

# Single-cell profiling of healthy human kidney reveals features of sex-based transcriptional programs and tissue-specific immunity

**Authors:** Caitriona M. McEvoy<sup>†1,2,3</sup>, Julia M. Murphy<sup>†1,2,4</sup>, Lin Zhang<sup>5</sup>, Sergi Clotet-Freixas<sup>^1,2</sup>, Jessica A. Mathews<sup>^1,2</sup>, James An<sup>1,2,4</sup>, Mehran Karimzadeh<sup>6</sup>, Delaram Pouyababahr<sup>7,8</sup>, Shenghui Su<sup>1,2</sup>, Olga Zaslaver<sup>7,8</sup>, Hannes Röst<sup>7,8</sup>, Madhurangi Arambewela<sup>1,2</sup>, Lewis Y. Liu<sup>1,2,4</sup>, Sally Zhang<sup>12</sup>, Keith A. Lawson<sup>12</sup>, Antonio Finelli<sup>12</sup>, Bo Wang<sup>6,9,10,11</sup>, Sonya A. MacParland<sup>1,2,4,10</sup>, Gary D. Bader<sup>7,8,12,13</sup>, Ana Konvalinka<sup>\*,1,2,3,10,14</sup>, Sarah Q. Crome<sup>\*,1,2,4</sup>

## Affiliations:

<sup>1</sup>Toronto General Hospital Research Institute, University Health Network; Toronto, ON, Canada.

<sup>2</sup>Ajmera Transplant Centre, University Health Network; Toronto, ON, Canada.

<sup>3</sup>Department of Medicine, Division of Nephrology, University Health Network; Toronto, ON, Canada.

<sup>4</sup>Department of Immunology, University of Toronto; Toronto, ON, Canada.

<sup>5</sup>Department of Statistical Sciences, University of Toronto; Toronto, ON, Canada.

<sup>6</sup>Vector Institute; Toronto, ON, Canada.

<sup>7</sup>Department of Molecular Genetics, University of Toronto; Toronto, ON, Canada.

<sup>8</sup>The Donnelly Centre, University of Toronto; Toronto, ON, Canada.

<sup>9</sup>Department of Computer Science, University of Toronto; Toronto, ON, Canada.

<sup>10</sup>Department of Laboratory Medicine and Pathobiology, University of Toronto; Toronto, ON, Canada.

<sup>11</sup>Peter Munk Cardiac Centre, University Health Network; Toronto, ON, Canada.

<sup>12</sup>Princess Margaret Cancer Centre, University Health Network; Toronto, ON, Canada

<sup>13</sup>The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Toronto, ON, Canada

<sup>14</sup>Institute of Medical Science, University of Toronto; Toronto, ON, Canada.

† co-first authorship

\* co-corresponding authorship

^ equal contribution

## \*co-corresponding authors:

Sarah Q. Crome ([sarah.crome@utoronto.ca](mailto:sarah.crome@utoronto.ca))

Ana Konvalinka ([Ana.Konvalinka@uhn.ca](mailto:Ana.Konvalinka@uhn.ca))

## ORCID identifiers:

CMM 0000-0002-3179-5542

JMM 0000-0002-0617-1666

SCF 0000-0002-6965-4403

JAM 0000-0003-2926-8222

MK 0000-0002-7324-6074

SAM 0000-0002-8036-1425

GDB 0000-0003-0185-8861

AK 0000-0001-6672-355X

SQC 0000-0001-5117-7453

**Word Count: 3950 in Main Text + 4203 Methods**

## Abbreviations

<b>AUC</b>	Area under the curve
<b>CCD</b>	Cortical collecting duct
<b>CNT</b>	Connecting tubule
<b>CTAL</b>	Cortical thick ascending limb of the loop of Henle
<b>DC</b>	Dendritic cell
<b>DCT</b>	Distal convoluted tubule
<b>Endo</b>	Endothelial
<b>IC-A</b>	Intercalated cells type A
<b>IC-B</b>	Intercalated cells type B
<b>IRI</b>	Ischemia-reperfusion injury
<b>LogFC</b>	Log Fold Change
<b>MP</b>	Mononuclear phagocyte
<b>MHC</b>	Major histocompatibility complex
<b>NK cell</b>	Natural killer cell
<b>Non-PT</b>	Non proximal tubular parenchymal cell
<b>PBMCs</b>	Peripheral blood mononuclear cells
<b>PGE2</b>	Prostaglandin E2
<b>PT</b>	Proximal tubule
<b>RBC</b>	Red blood cell
<b>scRNAseq</b>	Single cell RNA sequencing
<b>STC</b>	Scattered tubular cell
<b>TCA</b>	Tricarboxylic Acid
<b>TCR</b>	T cell receptor

# Abstract

Maintaining organ homeostasis requires complex functional synergy between distinct cell types, a snapshot of which is glimpsed through the simultaneously broad and granular analysis provided by single-cell atlases. Knowledge of the transcriptional programs underpinning the complex and specialized functions of human kidney cell populations at homeostasis is limited by difficulty accessing healthy, fresh tissue. Here, we present a single-cell perspective of healthy human kidney from 19 living donors, with equal contribution from males and females, profiling the transcriptome of 27677 high-quality cells to map healthy kidney at high resolution. Our sex-balanced dataset revealed sex-based differences in gene expression within proximal tubular cells, specifically, increased anti-oxidant metallothionein genes in females and the predominance of aerobic metabolism-related genes in males. Functional differences in metabolism were confirmed between male and female proximal tubular cells, with male cells exhibiting higher oxidative phosphorylation and higher levels of energy precursor metabolites. Within the immune niche, we identified kidney-specific lymphocyte populations with unique transcriptional profiles indicative of kidney-adapted functions and validated findings by flow cytometry. We observed significant heterogeneity in resident myeloid populations and identified an *MRC1<sup>+</sup> LYVE1<sup>+</sup> FOLR2<sup>+</sup> C1QC<sup>+</sup>* population as the predominant myeloid population in healthy kidney. This study provides a detailed cellular map of healthy human kidney, revealing novel insights into the complexity of renal parenchymal cells and kidney-resident immune populations.

## 22 Introduction

23 The complex functions of the kidney that maintain body homeostasis are executed by a diverse range  
 24 of specialized parenchymal cells residing in distinct compartments. Within tissues, resident immune  
 25 populations function in surveillance, maintenance of self-tolerance, response to infection and injury,  
 26 and interface with parenchymal cells to maintain tissue homeostasis<sup>1-3</sup>. There is limited  
 27 understanding of this network of kidney parenchymal and resident immune cells in humans due to  
 28 lack of access to healthy, fresh tissue. Much of our knowledge is based on studies that used kidneys  
 29 rejected for transplant or tumour-adjacent nephrectomy specimens, where parenchymal  
 30 populations can have altered molecular programs, and immune populations and their signalling  
 31 circuits may not be entirely reflective of the steady-state<sup>4,5</sup>. Further, sex-based dichotomy in gene  
 32 expression within human kidney cell populations has not been thoroughly examined, but is of great  
 33 significance to acute and chronic kidney disease, ischemia-reperfusion injury (IRI) and progression of  
 34 diabetic kidney disease, which exhibit a male preponderance<sup>6-8</sup>.

35 Here we present a detailed atlas of healthy human kidney using single cell RNA sequencing  
 36 (scRNAseq) of living donor kidney biopsies, capturing parenchymal and immune cell transcriptomes  
 37 reflective of a healthy state. We explore sex-based dichotomy in gene expression among kidney  
 38 populations, revealing altered transcriptional programs between male and female proximal tubular  
 39 cells, and perform an in-depth characterization of the immune niche in healthy, non-inflamed kidney.

## 41 Single-cell map of healthy human kidney

42 We examined the cellular landscape of human kidney using pre-implantation kidney biopsies from  
 43 19 sex-matched living kidney donors (**Fig. 1a, b**). Our dissociation method was developed to maximize  
 44 viability to preserve representation of rare and fragile cell populations, and we employed rigorous  
 45 quality control. Minimal immune cell representation in healthy kidney (~0.3% of cells captured)  
 46 necessitated CD45-enrichment for immune cells in 10/19 biopsy samples (5 female, 5 male) (**Fig. 1a**).

Of 27677 cells in our map, 6899 cells were from CD45-enriched samples, while 20778 cells were from non-CD45-enriched samples. Twenty-three clusters were identified including several distinct immune cell populations, alongside all anticipated parenchymal populations of the nephron (**Fig. 1c, Supplementary Fig. 1a**). Clusters were comprised of cells captured from multiple donors, there was no exceptional variability in cell cycle state across clusters, and most clusters had symmetrical distribution of donor sex (**Figure 1b-e, Supplemental Figure 1**).

As anticipated, Proximal Tubular (PT) cells comprised 75% of sequenced cells. Sub-clustering revealed 6 distinct clusters (PT1-PT6) (**Fig. 1d, Supplementary Fig. 2a**), with some heterogeneity between individuals, methods of sample preparation, and sexes noted (**Supplementary Fig. 2b**). PT segment-specific separation is evident; PT1, 4, and 6 are enriched for PT segment 1 (S1) marker *SLC5A2* and S1/2-abundant genes (*SLC7A7*, *ANK2*, *SLC4A4*, *SLC6A19*, *SLC22A8*), while PT2 shows increased expression of S3-abundant genes (*DCXR*, *AGXT*, *SLC22A7*, *SLC7A13*) (**Fig. 1e**)<sup>9,10</sup>. PT3 highly expresses dissociation stress-associated genes<sup>3</sup>, together with general (*LRP2*, *CUBN*) and segment-specific PT genes, indicating cell contributions from all PT segments (**Fig. 1e, Supplementary Fig. 2c**). PT5 (*VIM*<sup>+</sup>*S100A6*<sup>+</sup>*VCAM1*<sup>+</sup>*DCDC2*<sup>+</sup>*ANXA4*<sup>+</sup>) displays similarity to a putative regenerative PT population – termed ‘scattered tubular cells’ (STC)<sup>11,12</sup>. These genes also characterize a population which expands following IRI and is postulated to reflect failed PT repair, though expression was also observed in healthy kidney<sup>13</sup>. Some STC-associated genes were exclusively expressed by PT5 or PT3, while others were expressed in both populations (**Supplementary Fig. 2d-f**). This transcriptional overlap between the regenerative STC-like PT5 and stressed PT3 cells may indicate attempted initiation of repair in PT3 cells. Transcription factor analysis (**Supplementary Fig. 2g**) of PT5 genes revealed potential upstream regulators directing cell differentiation and migration (*SNAI2*, *ZNF217*), and epithelial phenotype maintenance (*ELF3*), alongside *NFE2L2* (*NRF2*), a key regulator of antioxidant and cytoprotective genes<sup>14</sup>. Predicted upstream regulators for PT3 (*EGR1*, *FOS*, and *JUN*)

are associated with oxidative stress and fibrogenesis. Predicted regulator ATF3 (protective in renal IRI<sup>15</sup>) supports potential reparative processes in this cluster (**Supplementary Fig. 2g**).

Fourteen non-PT parenchymal cell populations were identified<sup>9</sup> (**Fig. 1f-g**) including rare but important glomerular populations such as podocytes, mesangial cells, and parietal epithelial cells. We detected notable heterogeneity in CTAL and endothelial populations. Two CTAL subpopulations expressing *CLDN10* and *CLDN16*, respectively, identify cells with differing paracellular cation-resorption preferences in CLDN10-dominant (Na<sup>+</sup>) versus CLDN16-dominant tight junctions (Ca<sup>2+</sup>, Mg<sup>2+</sup>) (**Supplementary Fig. 3a-e**)<sup>16</sup>. Among endothelial subpopulations (Endo1-4) (**Fig. 1f**), we identified two populations (Endo1, Endo3) of peritubular capillary cells (*PLVAP*<sup>+</sup>*TMEM88*<sup>+</sup>*DNASE1L3*<sup>+</sup>) (**Supplementary Fig. 3a, f, g**). Endo1 expressed *ESM1* – required for VEGF-related maintenance of the peritubular capillary network<sup>17</sup>, while Endo3 expressed motility and angiogenesis markers *MARCKS*, *CLU*, *ACKR1*, *SEMA3D* (**Supplementary Fig. 3f**). Endo2 (*SOX17*<sup>+</sup>*SERPINE2*<sup>+</sup>*CLDN5*<sup>+</sup>*CXCL12*<sup>+</sup>) represents afferent arterioles and vasa recta, exhibiting reduced *KDR* expression and increased expression of extracellular matrix-encoding genes (**Supplementary Fig. 3g**). Endo4 expresses the glomerular microvascular endothelial cell markers *EDH3*, *SOST*, and *TBX3*, a transcriptional regulator critical to fenestrated glomerular endothelial development (**Supplementary Fig. 3f**)<sup>18</sup>.

## Identification of sex-based transcriptomic differences in proximal tubular cells

Leveraging the sex-balanced large sample size, we examined differences in gene expression in healthy human kidney between males and females. Using varimax-rotated principal component analysis, we examined individual kidney populations for separation due to donor sex, and observed a clear separation for the PT population (left panel in **Fig. 2a**, **Supplementary Fig. 4a**). Such separation was not evident in other cell populations, perhaps reflecting insufficient power with fewer cells. Consequently, subsequent analyses focused on PT cells. Using machine learning, we identified the most discriminant subset of genes in our dataset that could correctly classify cell sex. Model-1 (80

genes) correctly classified cell sex with an area under the curve (AUC) of 0.98 (training dataset), and an accuracy of 84% (validation dataset) (middle panel in **Fig. 2a, Supplementary Fig. 4b,c,f**). As X- and Y-linked genes potentially drive sex-biased effects<sup>19</sup>, we removed all sex chromosome-encoded genes and derived Model-2 (15 genes), which correctly classified cell sex in the training dataset (AUC 0.85), but had reduced accuracy (68%) in the validation set (**Supplementary Fig. 4d-f**). Using an independent single-cell kidney dataset for validation<sup>20</sup>, our gene signatures accurately classified cell sex in 79% (Model-1) and 66% (Model-2) of cells (**Supplementary Fig. 4f**). Next, we identified genes with significant differential expression between males and females (n=75 genes, p-value <0.05, LogFC>0.25) (right panel in **Fig. 2a**). As our conservative analysis excluded genes expressed uniquely by one sex (e.g. Y-chromosome-encoded genes), these genes (n=12) were added for downstream analyses (**Fig. 2b**). Results from our three analyses were compared (**Supplementary Table 1**). In agreement with previous studies<sup>21,22</sup>, the majority of the sex-biased genes uncovered are located in autosomes, rather than in sex chromosomes. Several sex-biased genes are consistent with previous reports of genes upregulated in murine male (*NAT8*, *FKBP5*, *KDM5D*, *DGKG*) and female (*MGST3*, *SLC3A1*, *CYP4A11*, *RPS29*) PT cells, respectively<sup>21-23</sup>.

Twenty-two genes featured in all three analyses (**Fig. 2c**), including 9 Y- and 3 X-chromosome encoded genes. An additional 18 genes featured in differential expression analysis (MAST+) and one other analysis (**Fig. 2c**). The X-chromosome genes reported are known to escape X-chromosome inactivation, explaining their higher expression in females<sup>19</sup>. Many of the autosomal-encoded genes or their family members are associated with primary sex determination (*SRSF5*<sup>24</sup>, *GATM*<sup>25</sup>, *GADD45A*), sex-biased expression (*CISH*, *SRSF5*, *ACTG1*, *GATM*, *AOX1*), or sex-specific effects (*SLC2A9*<sup>26</sup>). Intriguingly, many of the genes have established links with kidney disease, including *SLC27A2* (diabetic kidney disease)<sup>27</sup>, *SLC3A1* (cystinuria), and *GATM*<sup>28</sup>; while others are associated with hypoxia (*PHGD*, *CA12*), inflammation (*PPIA*), and genotoxic stress (*ASS1*). Metallothionein gene family members (*MT1F*, *MT1G*, *MT1H*), which encode cysteine-rich antioxidant proteins<sup>29</sup>, were

notably higher in females (**Fig. 2a,c**). Additional differentially expressed genes also relate to cysteine-glutathione availability and metabolism, including *SLC3A1*<sup>30</sup>, *MGST3*, and *HRASLS2*.

We next aimed to validate sex-biased gene expression profiles using commercially-available human primary PT cells from 3 male and 3 female independent healthy donors (**Supplementary Table 2**, age range of donors 50-59 years old). As expected, Y-linked genes *KDM5D*, *UTY*, and *EIF1AY* were exclusively expressed in male PT cells (**Fig. 2d**). We also studied the X-linked genes *EIF1AX* and *DDX3X*. While proposed as ‘X-inactivation escapees’, the extent of X-inactivation can be highly variable across genes, tissues, and individuals<sup>31</sup>. In agreement with our scRNAseq findings, primary female PT cells displayed increased transcript levels of *EIF1AX* and *DDX3X*, compared to male cells (**Fig. 2d**). Female sex is linked to lower oxidative stress markers in the kidney *in vivo*<sup>6</sup> but whether the sex of PT cells is a major contributor to this effect is unknown. Gene expression of *MT1F*, *MT1G*, *MT1H* was significantly increased in primary female PT cells, compared to male cells, as identified by scRNAseq and validated with qPCR in these independent donors (**Fig. 2a,c,d**). Of note, many of the transcripts exhibiting sex dimorphism in our scRNAseq analysis were absent when using matched single nucleus RNA sequencing, likely due to cytosolic or mitochondrial localization of the transcripts (**Supplementary Fig. 5**)

We next investigated the biological processes enriched among the genes showing sex-biased expression in PT cells. Pathway analysis (**Fig. 3a, Supplementary Table 3**) revealed processes related to amino acid metabolism, PT transport, and regulation of the inflammatory response as increased in females. Among the pathways increased in males, processes related to mitochondrial aerobic metabolism (‘oxidative phosphorylation’, ‘tricarboxylic acid (TCA) cycle’ and ‘electron transport chain’) predominated. Two additional metabolic processes, namely ‘generation of precursor metabolites’ and ‘nucleoside triphosphate metabolism’, were also enriched in males. To validate these observations, we studied functional differences in mitochondrial metabolism and precursor metabolite generation in male and female PT cells. We exposed primary male and female PT cells to



minimal media containing glucose and glutamine, which serve as mitochondrial substrates. We then measured their oxygen consumption rate (OCR), as a marker of mitochondrial respiration<sup>32</sup>. Supporting our pathway analysis, male PT cells showed a significant increase in OCR at baseline and after metabolic stress, compared to female PT cells (**Fig. 3b**). By calculating the corresponding areas under the OCR curves, we determined that male PT cells had a significantly higher basal respiration, ATP-linked respiration, maximal respiratory capacity, and reserve capacity than female cells (**Fig. 3c**). Together with mitochondrial respiration, glycolysis is a major mechanism of glucose-derived energy production<sup>33</sup>. Thus, a parallel increase in glycolysis and aerobic respiration is often indicative of a higher energy state<sup>34</sup>. Increased OCR in our male PT cells was linked to a significant increase in their glycolytic capacity (**Supplementary Fig. 6**), suggesting that they are energetically more active than female PT cells. Mitochondrial respiration results in the generation of two key energy precursors - NAD and ATP<sup>35</sup>. In line with increased aerobic metabolism, male PT cells exhibited a significant increase in the intracellular levels of NAD,  $\beta$ -nicotinamide mononucleotide (NAD precursor), ATP, and three additional nucleoside triphosphate metabolites - GTP, ITP, and UTP (**Fig. 3d**).

# **Immune landscape of healthy human kidney**

Despite the relative paucity of immune cells in healthy human kidney, we examined kidney-resident immune cells to delineate their steady-state phenotypes and functions. Sub-clustering of immune cells yielded 12 clusters (**Fig. 4a**). T cells ( $CD3E^+$ ), Natural Killer (NK) cells ( $NKG7^+CD3E^-$ ), and a small B cell population ( $CD79A^+$ ) mainly expressing the immunoglobulin chain *IGHM* were identified (**Fig. 4b**, **Supplementary Fig. 7a**). Plasma cells ( $CD38^+XBP1^+$ ) were scarce in healthy kidney tissue (**Supplementary Fig. 7b**). Myeloid clusters ( $CD68^+$ ) (**Fig. 4b**) displayed enrichment of phagocyte-related pathways including “receptor-mediated endocytosis”, “regulation of TLR signaling”, and “antigen processing and presentation via MHC class II” (**Supplementary Fig. 7c**).

170 T cell cluster T1 expressed CD4<sup>+</sup> T helper (Th) cell genes (*IL7R<sup>+</sup>CD40LG<sup>+</sup>LTB<sup>+</sup>*) and enrichment  
 171 of “T-helper cell differentiation” and “Interleukin-7-mediated signaling” pathways (**Fig. 4c**,  
 172 **Supplementary Fig. 7c**). T1 also included *CCR7<sup>+</sup>SELL<sup>+</sup>* cells, suggesting central memory T cell identity  
 173 (**Supplementary Fig. 8**)<sup>36</sup>. T2 demonstrates expression of a cytotoxic program (*GZMA*, *GZMB*, *GZMH*,  
 174 *GNLY*, *PRF1*) alongside NK receptor genes (*KLRD1*, *KLRG1*), consistent with effector memory T cell or  
 175 NKT cell identity (**Fig. 4c**), T2 also contained some gamma-delta ( $\gamma\delta$ ) T cells, marked by co-expression  
 176 of TCR chain components *TRDV2* and *TRDC* (**Fig. 4b**). T3 had sparse expression of resident memory T  
 177 cell (Trm) markers (*CXCR6*, *ITGA1*), while T4 was marked by high *GZMK* expression, a marker of  
 178 circulating age-associated memory T cells (**Fig. 4b, c**)<sup>37</sup>. FOXP3<sup>+</sup>CD4<sup>+</sup> regulatory T cells were notably  
 179 absent from scRNAseq and flow cytometry analyses (**Supplementary Fig. 9a**), while being observed  
 180 in kidney pathologies<sup>38,39</sup>, indicating they are likely recruited during inflammation. NK cell cluster NK1  
 181 displayed a cytotoxic gene program and broad *FCGR3A*(CD16) expression. Flow cytometry confirmed  
 182 ~95% of renal NK cells are CD56<sup>dim</sup>CD16<sup>+</sup>(**Supplementary Fig. 10a**). Low abundance of ILC2s, ILC3s  
 183 and CD56<sup>bright</sup> NK cells was suggested by a predictive classifier and confirmed by flow cytometry  
 184 (**Supplementary Fig. 10b, c**).

185 As we noted differences in our lymphocytes signatures to those reported using other tissue  
 186 sources, we directly compared lymphocytes in living donor kidney with tumor-unaffected renal  
 187 tissue. We confirmed the presence of many similar immune populations across tissue sources, yet  
 188 also observed differences in abundance and transcriptional signatures. When T cell and NK cell  
 189 clusters were compared between these different tissue sources, alterations in checkpoint molecule  
 190 expression (i.e *TIGIT*, *CTLA4*, *PDCD1*) were noted, with some of these differences also being observed  
 191 at the protein level. We also observed high donor heterogeneity in immune infiltration and generally  
 192 a greater proportion of immune cells in nephrectomy specimens, supporting the immune niche can  
 193 be altered from healthy kidney.

Mononuclear phagocytes (MP) acquire tissue-adapted phenotypes and functions<sup>40</sup>.

Definitively attributing macrophage or DC identity to myeloid populations based on gene expression alone is particularly challenging within the kidney due to a lack of consensus on lineage defining markers<sup>41</sup> and here they are annotated more generally as five MP populations. Cluster MP1 highly expressed complement components (*C1QA*, *C1QB*, *C1QC*) and markers of alternative macrophage activation or anti-inflammatory function (*CD163*, *LYVE1*, *STAB1*, *MRC1*, *VSIG4*, *FOLR2*) (**Fig. 4b-c, Supplementary Fig. 12**). Efferocytosis receptor *MERTK* expression supports homeostasis or repair functions (**Supplementary Fig. 12**). MP3 contained cells expressing cDC2 markers (*CLEC10A*, *CD1C*), alongside a subgroup of cells co-expressing lipid-associated genes (*CD9*, *TREM2*, *APOE*, *APOC1*) (**Fig. 4b**). Similar populations have been identified as kidney-resident macrophages and are expanded in fibrotic tissues<sup>42</sup>. MP2 and MP4 (*FCGR3A*<sup>+</sup>*SIGLEC10*<sup>+</sup>*FCN1*<sup>+</sup>) resemble CD16<sup>+</sup> non-classical monocytes (**Fig. 4b-c, Supplementary Fig. 12**). MP4 had elevated expression of *IL1B*, MHC Class-II genes, and *CX3CR1* while MP2 had higher expression of *CXCR4* and *FPR1* (**Supplementary Fig. 7d**). MP5 expressed markers of classical CD14<sup>+</sup> monocytes (*S100A8*, *S100A9*, *CD14*, *VCAN*), yet was predominantly from one individual with elevated hemoglobin transcripts, indicative of increased circulating cells in this particular sample (**Fig. 4b, c, Supplementary Fig. 7e**). Flow cytometry confirmed greater abundance of CD16<sup>+</sup> cells in kidney relative to blood, as well as low proportions of CD14<sup>+</sup>CD16<sup>-</sup> MPs resembling MP5 and the presence of MRC1<sup>+</sup>HLA-DR<sup>+</sup> MPs in kidney that align with MP1 (**Supplementary Fig. 10e, f**).

## Identification of a distinct resident macrophage population in healthy kidney

Due to unique aspects of our study, including short ischemic times to which resident macrophages are especially sensitive<sup>43,44</sup>, and use of flushed living donor-derived kidney tissue, we examined shared and unique MP populations in healthy kidney compared to those reported previously in kidney tissue from other sources. *CD68*<sup>+</sup> cells from three prior studies<sup>3,45,46</sup> were

classified to match cluster identities of our study. MPs from these studies most resembled MP5 (classical CD14<sup>+</sup> monocyte-like), the lowest abundance MP cluster in living donor samples (**Supplementary Fig. 13a**). MP3 (DC-like and lipid-associated MPs) as well as MP2 and MP4 (CD16<sup>+</sup> non-classical monocyte-like) were shared across datasets. Strikingly, few cells from these studies corresponded to MP1 (resident macrophages) – the largest MP population in living donor kidney. Next, CD68<sup>+</sup> cells from these prior studies<sup>3,45,46</sup> and our study were merged, identifying five myeloid cell states (CS) across all studies (**Fig. 3d**). Based on transcriptomic profiles, CS2 and CS4 include resident macrophages and antigen-presenting cells, CS0 is consistent with non-classical CD16<sup>+</sup> monocytes, CS3 represents classical CD14<sup>+</sup> monocytes and CS1 may represent a transition state, supported by trajectory analysis (**Supplementary Fig. 13b, c**). CS2, which was almost entirely comprised of living donor kidney cells (**Supplementary Fig. 13b**), is defined by expression of genes associated with alternatively activated macrophages (*C1QA/B/C*<sup>+</sup>*RNASE1*<sup>+</sup>*CD163*<sup>+</sup>*LYVE1*<sup>+</sup>*FOLR2*<sup>+</sup>), in contrast to all other CS which expressed markers associated with monocytes and classically activated macrophages (*S100* family members, *FCN1*, *LYZ*, and pro-inflammatory *SOD2*) (**Fig. 4d**, **Supplementary Fig. 13b**). CS2 constitutes the predominant MP population in healthy kidney (MP1), while CS3 and CS4 abundance is limited (**Fig. 4e**)

### Kidney-resident lymphocytes are antigen-experienced with distinct gene expression

Due to unexpected heterogeneity and novel transcriptional profiles in kidney lymphocyte populations (**Fig. 4a-c**), we directly compared lymphocyte proportions, signatures, and phenotypes to those in healthy donor blood. Increased proportions of NK (CD3<sup>-</sup>CD56<sup>+</sup>) and NKT cells (CD3<sup>+</sup>CD56<sup>+</sup>) were noted in kidney, while T cell (CD3<sup>+</sup>CD56<sup>-</sup>) abundance was unchanged (**Fig. 5a**). CD8<sup>+</sup> T cells were present in higher proportions than CD4<sup>+</sup> T cells in kidney and the presence of  $\gamma\delta$ T cells was validated by flow cytometry (**Fig. 5b**, **Supplementary Fig. 9a**).

243 To identify specific markers and transcriptional profiles of kidney-resident lymphocytes, we  
 244 integrated our dataset with public PBMC scRNA-seq datasets<sup>47,48</sup>(**Supplementary Fig. 14a-j,**  
 245 **Supplementary Table 4**) and validated differences by flow cytometry. Unsurprisingly, blood  
 246 lymphocytes exhibited higher expression of naïve T cell genes (*CCR7*, *SELL*, *LEF1*, *TCF7*). In contrast,  
 247 the tissue residency-associated transcription factor *PRDM1* (BLIMP-1)<sup>49</sup> was upregulated in kidney  
 248 lymphocytes, as was *CD69*, which marks Trms in several organs and prevents tissue egress via S1PR1  
 249 antagonism<sup>50</sup> (**Supplementary Fig. 14j**). Antigen-experienced T cells upregulate CD45RO and can  
 250 become Trm<sup>51</sup>. 60-98% of kidney CD4<sup>+</sup> and CD8<sup>+</sup> T cells were CD45RO<sup>+</sup> in contrast to low proportions  
 251 of memory T cells in blood (**Fig. 5c**). NK cells with memory functions may also express CD45RO<sup>52</sup>;  
 252 however, this was not observed in renal NK cells (**Fig. 5c**). Flow cytometry confirmed elevated CD69  
 253 on T cells and NK cells, with CD69-CD103 co-expression by CD8<sup>+</sup> T cells, consistent with a Trm  
 254 phenotype (**Supplementary Fig. 9c**). Further characterization of memory CD4<sup>+</sup> T helper (Th) cell  
 255 subsets revealed enrichment of Th1/17 cells with reduced Th2 marker expression (**Fig. 5d,**  
 256 **Supplementary Fig. 9b**).

257 We also sought to validate Granzyme K production in kidney lymphocytes, as T4 cluster was  
 258 marked by high *GZMK* expression. In agreement with scRNAseq findings, Granzyme K was detected  
 259 in 21% of kidney T cells (**Fig. 5e**), with minimal co-expression with Granzyme B, indicating that  
 260 Granzyme K<sup>+</sup> T cells form a distinct subset of renal T cells (**Fig. 5e**). Most Granzyme K<sup>+</sup> T cells also did  
 261 not have detectable perforin expression (**Fig. 5e**), in line with Granzyme K produced by these T cells  
 262 having extracellular functions rather than the canonical cytolytic function of granzymes dependent  
 263 on intracellular delivery via perforin.

264 Kidney lymphocytes were distinguished from circulating lymphocytes by elevated expression  
 265 of chemokine receptors (*CXCR4*, *CXCR6*), integrin components (*ITGB1*, *ITGA4*), and inhibitory NK  
 266 receptors (*KLRD1*, *KLRC1*) (**Fig. 5f, Supplementary Fig. 14j**). Flow cytometry confirmed VLA-4 integrin  
 267 components  $\alpha 4$  (CD49d) and  $\beta 1$  (CD29) were highly expressed in renal T cells suggesting VLA-4

contributes to their residency or function (**Fig. 5g**). This is consistent with expression of VLA-4 ligands fibronectin and VCAM-1 in kidney<sup>53</sup>. Kidney NK cells have higher levels of CD69 compared to circulating NK cells, while no difference in CD29 or CD49d was detected (**Fig. 5h**). Finally, CXCR6 protein expression was elevated on kidney T and NK cells, while CXCR4 was not, despite high gene expression (**Fig. 5g, h, i**). Notably, renal myeloid cells expressed *CXCL16*, the chemokine ligand for CXCR6, indicating participation in lymphocyte recruitment, supported by significant aggregate rank scores using cell-cell communication inference (**Supplementary Fig. 9d, Supplementary Tables 5, 6**).

Other differentially expressed genes suggest tissue-adapted function of kidney lymphocytes. *AREG*, encoding the growth factor amphiregulin, was highly expressed by NK1 and validated by flow cytometry (**Supplementary Fig. 10d, Supplementary Fig. 11f, g**), suggesting tissue-reparative functions. The prostaglandin E2 (PGE2) receptor *PTGER4* and prostaglandin D synthase *PTGDS* were upregulated (**Supplementary Fig. 14j**), indicating kidney lymphocytes synthesize and recognize prostaglandins, known mediators of kidney function<sup>54</sup>. PGE2 promotes Th17 and Th1/17 cell development and function, perhaps explaining Th1/17 cell enrichment in kidney (**Fig. 4d**)<sup>55</sup>. Collectively these studies capture the heterogeneity of myeloid and lymphocyte populations within healthy human kidney and provide an important reference of immune cell phenotypes and functions at steady state.

## Discussion

We present a scRNAseq atlas of healthy human kidney using biopsies from living donors. Our resolution of healthy kidney PT, endothelial, epithelial, and immune subpopulations will inform future studies addressing underlying mechanisms of kidney pathologies, including chronic kidney disease, fibrosis, IRI, renal cancer and allograft rejection.

The sex-balanced design in the present study enabled novel examination of sex-based dichotomy in gene expression among human kidney cell populations. Prior studies were constrained

by small sample size and use of animal models, or instead used bulk transcriptional analysis where sex-specific signatures of individual kidney cell populations cannot be resolved<sup>19,23,57</sup>. Our study is aligned with the conclusion of scRNAseq studies in mouse by Ransick *et al.*<sup>23</sup> that PT cells are sexually dimorphic. However, the overlap in sexually dimorphic PT genes between human and mouse is small, perhaps due to distinct orthologues in mouse, small number of samples sequenced, or true biological differences between human and mouse.

We report striking sex-based transcriptional differences in PT cells, suggesting higher baseline metabolic activity in males, and enhanced expression of antioxidant genes in females. We validated these sex-based observations at the level of gene expression, metabolite generation, and metabolic function *in vitro*. Increased oxidative stress is reported in males<sup>58</sup>, while female sex hormones augment antioxidant gene transcription<sup>59</sup>. Metallothionein genes (*MT1F*, *MT1G*, *MT1H*), which are potent endogenous antioxidants<sup>60</sup>, were increased in female PT cells. Metallothionein depletion exacerbates diabetic and hypoxia-induced kidney injury<sup>61,62</sup>, whereas augmented expression is protective<sup>63</sup>. Several sex-altered genes further relate to cysteine-glutathione metabolism. Glutathione is critical to cellular antioxidant defences<sup>64</sup> and glutathione metabolism exhibits sexual dimorphism<sup>22,65</sup>. These sex-based differences in PT gene expression discovered by use of scRNAseq which can capture transcripts localized to the mitochondria and cytosol, may provide insights into the well-recognized, but previously unexplained sexual dimorphism observed in most kidney diseases. In particular, why females may be less susceptible to metabolism-related kidney injury<sup>6-8,66,67</sup>.

Our study provides a steady-state map of the kidney immune niche. Kidney T cells are predominantly Trms and exhibit unique phenotypes previously unreported in kidney, including Granzyme K<sup>+</sup> T cells. The function of Granzyme K<sup>+</sup> T cells in humans is poorly characterized, and here we show that Granzyme K<sup>+</sup> T cells are a distinct subset separate from Granzyme B<sup>+</sup>Perforin<sup>+</sup> T cells in

the kidney. The lack of perforin co-expression suggests that Granzyme K produced by renal T cells may have extracellular targets, such as inducing endothelial cell activation<sup>68</sup>, promoting sensitivity to LPS-induced inflammation<sup>69</sup>, and regulating angiogenesis<sup>70</sup>.

Renal CD4<sup>+</sup> memory Th cells are skewed towards a Th1/17 phenotype, which may be relevant to Th17-related kidney diseases including glomerulonephritis, lupus nephritis, and transplant rejection<sup>71,72</sup>. Renal abundance of CD56<sup>+</sup>CD16<sup>+</sup> NK cells with high expression of amphiregulin compared to circulating NK cells suggests non-canonical tissue-adapted functions. We demonstrate an enrichment of a resident macrophage population with little-to-no presence in prior datasets from discarded deceased donor or tumor nephrectomy specimens, suggesting altered kidney environments impact this myeloid population. Indeed, sensitivity of self-renewing resident macrophage populations to extended ischemic injury and inflammation is reported<sup>44</sup>. Additional comparison of lymphocyte populations in tumor-unaffected versus living donor renal tissue revealed alterations in tumor-unaffected tissue relative to the steady-state immune niche in healthy living donor kidney. Increased B and T cell proportions, increased expression of activation and exhaustion-associated molecules by lymphocytes, in addition to a trend for increased immune infiltration in nephrectomy specimens was observed (**Supplementary Fig. 11**), in agreement with prior reports that tumour-affected kidneys can have altered immune infiltrates<sup>5,56</sup>. Future studies exploring alterations in immune cells in tumor-unaffected kidney tissue of renal cancer patients may have implications for development of immunotherapies.

Collectively, our description of healthy human kidney provides a reference point for understanding the cellular basis of kidney disease development, represents a ‘normal’ target for stem cell-derived kidney organoids, and expands our understanding of the complexity of sex-based gene expression and kidney-resident immune populations.



## 343 References

- 344 1. Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic  
345 concepts and clinical implications. *Nat Rev Immunol* 2013;13:738-53.
- 346 2. Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J. Dendritic cells and  
347 macrophages in the kidney: a spectrum of good and evil. *Nature reviews Nephrology* 2014;10:625-  
348 43.
- 349 3. Stewart BJ, Ferdinand JR, Young MD, et al. Spatiotemporal immune zonation of the human  
350 kidney. *Science* 2019;365:1461-6.
- 351 4. Saat TC, Susa D, Roest HP, et al. A comparison of inflammatory, cytoprotective and injury  
352 gene expression profiles in kidneys from brain death and cardiac death donors. *Transplantation*  
353 2014;98:15-21.
- 354 5. Damman J, Bloks VW, Daha MR, et al. Hypoxia and Complement-and-Coagulation Pathways  
355 in the Deceased Organ Donor as the Major Target for Intervention to Improve Renal Allograft  
356 Outcome. *Transplantation* 2015;99:1293-300.
- 357 6. Clotet S, Soler MJ, Riera M, et al. Stable Isotope Labeling with Amino Acids (SILAC)-Based  
358 Proteomics of Primary Human Kidney Cells Reveals a Novel Link between Male Sex Hormones and  
359 Impaired Energy Metabolism in Diabetic Kidney Disease. *Mol Cell Proteomics* 2017;16:368-85.
- 360 7. Aufhauser DD, Jr., Wang Z, Murken DR, et al. Improved renal ischemia tolerance in females  
361 influences kidney transplantation outcomes. *J Clin Invest* 2016;126:1968-77.
- 362 8. Neugarten J, Golestaneh L. Female sex reduces the risk of hospital-associated acute kidney  
363 injury: a meta-analysis. *BMC Nephrol* 2018;19:314.
- 364 9. Clark JZ, Chen L, Chou CL, Jung HJ, Lee JW, Knepper MA. Representation and relative  
365 abundance of cell-type selective markers in whole-kidney RNA-Seq data. *Kidney Int* 2019;95:787-  
366 96.
- 367 10. Wu H, Uchimura K, Donnelly EL, Kirita Y, Morris SA, Humphreys BD. Comparative Analysis  
368 and Refinement of Human PSC-Derived Kidney Organoid Differentiation with Single-Cell  
369 Transcriptomics. *Cell Stem Cell* 2018;23:869-81 e8.
- 370 11. Smeets B, Boor P, Dijkman H, et al. Proximal tubular cells contain a phenotypically distinct,  
371 scattered cell population involved in tubular regeneration. *J Pathol* 2013;229:645-59.
- 372 12. Berger K, Bangen JM, Hammerich L, et al. Origin of regenerating tubular cells after acute  
373 kidney injury. *Proc Natl Acad Sci U S A* 2014;111:1533-8.
- 374 13. Kirita Y, Wu H, Uchimura K, Wilson PC, Humphreys BD. Cell profiling of mouse acute kidney  
375 injury reveals conserved cellular responses to injury. *Proc Natl Acad Sci U S A* 2020;117:15874-83.
- 376 14. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: Pivotal roles in  
377 inflammation. *Biochim Biophys Acta Mol Basis Dis* 2017;1863:585-97.
- 378 15. Yoshida T, Sugiura H, Mitobe M, et al. ATF3 protects against renal ischemia-reperfusion  
379 injury. *J Am Soc Nephrol* 2008;19:217-24.
- 380 16. Milatz S, Himmerkus N, Wulfmeyer VC, et al. Mosaic expression of claudins in thick  
381 ascending limbs of Henle results in spatial separation of paracellular Na<sup>+</sup> and Mg<sup>2+</sup> transport. *Proc*  
382 *Natl Acad Sci U S A* 2017;114:E219-E27.
- 383 17. Rocha SF, Schiller M, Jing D, et al. Esm1 modulates endothelial tip cell behavior and vascular  
384 permeability by enhancing VEGF bioavailability. *Circ Res* 2014;115:581-90.
- 385 18. Barry DM, McMillan EA, Kunar B, et al. Molecular determinants of nephron vascular  
386 specialization in the kidney. *Nat Commun* 2019;10:5705.
- 387 19. Oliva M, Munoz-Aguirre M, Kim-Hellmuth S, et al. The impact of sex on gene expression  
388 across human tissues. *Science* 2020;369.
- 389 20. Liao J, Yu Z, Chen Y, et al. Single-cell RNA sequencing of human kidney. *Sci Data* 2020;7:4.

21. Wu H, Lai CF, Chang-Panesso M, Humphreys BD. Proximal Tubule Translational Profiling during Kidney Fibrosis Reveals Proinflammatory and Long Noncoding RNA Expression Patterns with Sexual Dimorphism. *J Am Soc Nephrol* 2020;31:23-38.
22. Vinas JL, Porter CJ, Douvris A, et al. Sex diversity in proximal tubule and endothelial gene expression in mice with ischemic acute kidney injury. *Clin Sci (Lond)* 2020;134:1887-909.
23. Ransick A, Lindstrom NO, Liu J, et al. Single-Cell Profiling Reveals Sex, Lineage, and Regional Diversity in the Mouse Kidney. *Dev Cell* 2019;51:399-413 e7.
24. Planells B, Gomez-Redondo I, Pericuesta E, Lonergan P, Gutierrez-Adan A. Differential isoform expression and alternative splicing in sex determination in mice. *BMC Genomics* 2019;20:202.
25. Clement TM, Anway MD, Uzumcu M, Skinner MK. Regulation of the gonadal transcriptome during sex determination and testis morphogenesis: comparative candidate genes. *Reproduction* 2007;134:455-72.
26. Doring A, Gieger C, Mehta D, et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. *Nat Genet* 2008;40:430-6.
27. Khan S, Gaivin R, Abramovich C, Boylan M, Calles J, Schelling JR. Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression. *JCI Insight* 2020;5.
28. Reichold M, Klootwijk ED, Reinders J, et al. Glycine Amidinotransferase (GATM), Renal Fanconi Syndrome, and Kidney Failure. *J Am Soc Nephrol* 2018;29:1849-58.
29. Ruttkay-Nedecky B, Nejdil L, Gumulec J, et al. The role of metallothionein in oxidative stress. *Int J Mol Sci* 2013;14:6044-66.
30. Woodard LE, Welch RC, Veach RA, et al. Metabolic consequences of cystinuria. *BMC Nephrol* 2019;20:227.
31. Tukiainen T, Villani AC, Yen A, et al. Landscape of X chromosome inactivation across human tissues. *Nature* 2017;550:244-8.
32. Smolina N, Bruton J, Kostareva A, Sejersen T. Assaying Mitochondrial Respiration as an Indicator of Cellular Metabolism and Fitness. *Methods Mol Biol* 2017;1601:79-87.
33. Chaudhry R, Varacallo M. Biochemistry, Glycolysis. StatPearls. Treasure Island (FL)2021.
34. Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? *Biochim Biophys Acta* 2011;1807:552-61.
35. Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. *Cell Metab* 2015;22:31-53.
36. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. *Nat Med* 2015;21:688-97.
37. Mogilenko DA, Shpynov O, Andhey PS, et al. Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK(+) CD8(+) T Cells as Conserved Hallmark of Inflammaging. *Immunity* 2021;54:99-115 e12.
38. Nehar-Belaid D, Hong S, Marches R, et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level. *Nat Immunol* 2020;21:1094-106.
39. Sakai R, Ito M, Komai K, et al. Kidney GATA3(+) regulatory T cells play roles in the convalescence stage after antibody-mediated renal injury. *Cell Mol Immunol* 2021;18:1249-61.
40. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. *Immunity* 2014;41:21-35.
41. Gottschalk C, Kurts C. The Debate about Dendritic Cells and Macrophages in the Kidney. *Front Immunol* 2015;6:435.
42. Ramachandran P, Dobie R, Wilson-Kanamori JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. *Nature* 2019;575:512-8.
43. Liu F, Dai S, Feng D, et al. Distinct fate, dynamics and niches of renal macrophages of bone marrow or embryonic origins. *Nat Commun* 2020;11:2280.

- 439 44. Yue S, Zhou H, Wang X, Busuttil RW, Kupiec-Weglinski JW, Zhai Y. Prolonged Ischemia  
440 Triggers Necrotic Depletion of Tissue-Resident Macrophages To Facilitate Inflammatory Immune  
441 Activation in Liver Ischemia Reperfusion Injury. *J Immunol* 2017;198:3588-95.
- 442 45. Zimmerman KA, Bentley MR, Lever JM, et al. Single-Cell RNA Sequencing Identifies  
443 Candidate Renal Resident Macrophage Gene Expression Signatures across Species. *J Am Soc*  
444 *Nephrol* 2019;30:767-81.
- 445 46. Arguello RJ, Combes AJ, Char R, et al. SCENITH: A Flow Cytometry-Based Method to  
446 Functionally Profile Energy Metabolism with Single-Cell Resolution. *Cell Metab* 2020;32:1063-75 e7.
- 447 47. Wang X, Sun Z, Zhang Y, et al. BREM-SC: a bayesian random effects mixture model for joint  
448 clustering single cell multi-omics data. *Nucleic Acids Res* 2020;48:5814-24.
- 449 48. [https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.2/5k\\_pbmc\\_v3](https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.2/5k_pbmc_v3).  
450 2019. at [https://support.10xgenomics.com/single-cell-gene-](https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.2/5k_pbmc_v3)  
451 [expression/datasets/3.0.2/5k\\_pbmc\\_v3](https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.2/5k_pbmc_v3).)
- 452 49. Mackay LK, Minnich M, Kragten NA, et al. Hobit and Blimp1 instruct a universal  
453 transcriptional program of tissue residency in lymphocytes. *Science* 2016;352:459-63.
- 454 50. Cibrian D, Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. *Eur J*  
455 *Immunol* 2017;47:946-53.
- 456 51. Clark RA. Resident memory T cells in human health and disease. *Sci Transl Med*  
457 2015;7:269rv1.
- 458 52. Fu X, Liu Y, Li L, et al. Human natural killer cells expressing the memory-associated marker  
459 CD45RO from tuberculous pleurisy respond more strongly and rapidly than CD45RO- natural killer  
460 cells following stimulation with interleukin-12. *Immunology* 2011;134:41-9.
- 461 53. Chakravorty SJ, Howie AJ, Cockwell P, Adu D, Savage CO. T lymphocyte adhesion  
462 mechanisms within inflamed human kidney: studies with a Stamper-Woodruff assay. *Am J Pathol*  
463 1999;154:503-14.
- 464 54. Kim GH. Renal effects of prostaglandins and cyclooxygenase-2 inhibitors. *Electrolyte Blood*  
465 *Press* 2008;6:35-41.
- 466 55. Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin E2 regulates Th17 cell differentiation  
467 and function through cyclic AMP and EP2/EP4 receptor signaling. *J Exp Med* 2009;206:535-48.
- 468 56. Aran D, Camarda R, Odegaard J, et al. Comprehensive analysis of normal adjacent to tumor  
469 transcriptomes. *Nat Commun* 2017;8:1077.
- 470 57. Si H, Banga RS, Kapitsinou P, et al. Human and murine kidneys show gender- and species-  
471 specific gene expression differences in response to injury. *PLoS One* 2009;4:e4802.
- 472 58. Tower J, Pomatto LCD, Davies KJA. Sex differences in the response to oxidative and  
473 proteolytic stress. *Redox Biol* 2020;31:101488.
- 474 59. Pan JS, Sheikh-Hamad D. Mitochondrial dysfunction in acute kidney injury and sex-specific  
475 implications. *Med Res Arch* 2019;7.
- 476 60. Schanz M, Schaaf L, Dippon J, et al. Renal effects of metallothionein induction by zinc in  
477 vitro and in vivo. *BMC Nephrol* 2017;18:91.
- 478 61. Tachibana H, Ogawa D, Sogawa N, et al. Metallothionein deficiency exacerbates diabetic  
479 nephropathy in streptozotocin-induced diabetic mice. *Am J Physiol Renal Physiol* 2014;306:F105-  
480 15.
- 481 62. Wu H, Zhou S, Kong L, et al. Metallothionein deletion exacerbates intermittent hypoxia-  
482 induced renal injury in mice. *Toxicol Lett* 2015;232:340-8.
- 483 63. Park L, Min D, Kim H, et al. Tat-enhanced delivery of metallothionein can partially prevent  
484 the development of diabetes. *Free Radic Biol Med* 2011;51:1666-74.
- 485 64. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications  
486 for health. *J Nutr* 2004;134:489-92.
- 487 65. Wang L, Ahn YJ, Asmis R. Sexual dimorphism in glutathione metabolism and glutathione-  
488 dependent responses. *Redox Biol* 2020;31:101410.

66. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. American journal of kidney diseases : the official journal of the National Kidney Foundation 2017;69:A7-A8.
67. Clotet-Freixas S, Soler MJ, Palau V, et al. Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy. Lab Invest 2018;98:1237-49.
68. Sharma M, Merkulova Y, Raithatha S, et al. Extracellular granzyme K mediates endothelial activation through the cleavage of protease-activated receptor-1. FEBS J 2016;283:1734-47.
69. Wensink AC, Kemp V, Fermie J, et al. Granzyme K synergistically potentiates LPS-induced cytokine responses in human monocytes. Proc Natl Acad Sci U S A 2014;111:5974-9.
70. Li S, van Dijk CGM, Meeldijk J, et al. Extracellular Granzyme K Modulates Angiogenesis by Regulating Soluble VEGFR1 Release From Endothelial Cells. Front Oncol 2021;11:681967.
71. Turner JE, Paust HJ, Steinmetz OM, Panzer U. The Th17 immune response in renal inflammation. Kidney Int 2010;77:1070-5.
72. Chung BH, Yang CW, Cho ML. Clinical significance of Th17 cells in kidney transplantation. Korean J Intern Med 2018;33:860-6.

# **Acknowledgments:**

First and foremost, we would like to thank the kidney transplant patients who made this work possible. We would also like to thank the nurses, physicians and surgeons at Toronto General Hospital and the Ajmera Transplant Centre Biobank for efforts to obtain tissue samples, and acknowledge technical support provided by the Princess Margaret Genomics Centre, particularly Troy Ketela and Julissa Tsao, and the Princess Margaret Cancer Centre flow cytometry core. CMM was supported by the Menkes Family Fellowship and an Ajmera Transplant Centre fellowship. JMM was supported a QE II/Aventis Pasteur Graduate Scholarship and a Peterborough K.M. Hunter Foundation scholarship. This work supported by funding from the Canadian Institutes for Health Research (CIHR) grant 168960 to SQC and AK and the Ajmera Transplant Centre/Toronto General and Western Hospital Foundation (TGWHF). SQC was also supported by the Medicine by Design program (Canada First Research Excellence Fund) and Canada Foundation for Innovation (CFI) grant 38308. AK was supported by Kidney Foundation of Canada (KFOC) Predictive Biomarker grant KFOC160010, CIHR 347479, CFI grant 37205, KFOC Biomedical Research grant KFOC160010, and Kidney Research Scientist Core Education and National Training (KRESCENT) program grants CIHR148204, KRES160004, and KRES160005, as well as funding from TGWHF (TGTWF 1617-464; TGTWF MKFTR 1718-1268).

523

524 **Author contributions:**

525 CMM, JMM, AK, and SQC designed and implemented the study. AK and SS established the ATC  
 526 biobank and the infrastructure required for sample retrieval. SS, CMM, JMM, SZ, KAL, AF and AK  
 527 liaised with patient care teams to obtain tissues for study. CMM, JMM, JAM, SCF, JA, AK and SQC  
 528 developed tissue dissociation protocols with input from LL and SAM, and performed experiments.  
 529 SCF, OZ, HR, RA, contributed to PT validation experiments. CMM, JMM and LZ designed and  
 530 implemented the bioinformatic pipeline with advice and assistance from MK, DP, BW, GDB, AK and  
 531 SQC. CMM, JMM, SAM, AK and SQC provided tissue and immune compartment expertise and  
 532 annotated cell types. BW, SAM, GDB, AK, and SQC supervised the work. CMM, JMM, AK, and SQC  
 533 wrote the manuscript, which all authors reviewed and edited.

534

535 **Competing interests:** Authors declare that they have no competing interests

536

537 **Materials and correspondence**

538 Correspondence and requests for materials should be addressed to Dr. Sarah Crome  
 539 (sarah.crome@utoronto.ca) and Dr. Ana Konvalinka (Ana.Konvalinka@uhn.ca)

540

541 Supplementary Information is available for this paper.

542

543

544

545

546

547

548

549

550


551

552





554



555

556

557

558

559


560

561

562


563

**Figure 1. Identification and annotation of kidney parenchymal cells.** (a) Different cell type proportions were captured by sequencing total kidney homogenate and CD45-enriched samples to create the total combined dataset. (b) UMAP clustering of total combined dataset with cell type annotations. (c) Graphical depiction of location of nephron cell types captured within the data. (d) UMAP plot of compartment-specific analysis of 20772 proximal tubular cells, comprising 6 clusters. (e) Heat map showing the expression levels of cluster marker genes. (f) UMAP plot of compartment-specific analysis of 4436 non-proximal tubular parenchymal cells, with 14 cell populations represented, including four distinct endothelial clusters. (g) Heat map showing the expression levels of cell type marker genes across the 14 non-PT cell populations.




**Figure 2. Identifying genes differentially expressed between male and female proximal tubular cells.** (a) 2-Dimensional plots of Varimax-rotated PCA and sPLS-DA showing separation of male and female cells, and volcano plot showing differential expression of genes between sexes from MAST analysis with sample random effect. (b) Genes expressed exclusively by all samples of one sex and none of the opposite sex, which were added to the MAST results for comparison across methods in c. (c) Venn diagram depicting genes identified through each analysis, with bubble plots highlighting genes identified by all three methods or by MAST plus one additional method. The size of the circle is proportional to absolute logFC and the colour indicates whether the gene was higher in male (orange) or female (dark purple) PT cells. (d) Differences in gene expression of *KDM5D* ( $p < 0.0001$ ,  $t = 17.32$ ,  $df = 30$ ), *UTY* ( $p < 0.0001$ ,  $t = 18.75$ ,  $df = 30$ ), *EIF1AY* ( $p < 0.0001$ ,  $t = 18.04$ ,  $df = 30$ ), *EIF1AX* ( $p < 0.0001$ ,  $t = 9.077$ ,  $df = 29$ ), *DDX3X* ( $p < 0.0001$ ,  $t = 5.619$ ,  $df = 29$ ), *MT1F* ( $p < 0.0001$ ,  $t = 16.04$ ,  $df = 30$ ), *MT1G* ( $p < 0.0001$ ,  $u = 0$ ), and *MT1H* ( $p < 0.0001$ ,  $t = 6.286$ ,  $df = 30$ ) were determined in primary male and female PT cells, and normalized to RPL31 ( $n = 3$  donors/sex;  $n = 4-6$  replicates/donor). Group-to-group differences were assessed using two-tailed unpaired t-tests for variables following a normal distribution, and Mann-Whitney tests for variables with a non-parametric distribution. \*\*\*\* $p < 0.0001$ . PT, proximal tubule.






**Figure 3. Sex differences in the mitochondrial respiration and energy precursor metabolism of proximal tubular cells.** (a) Depiction of selected significant (FDR<0.25) terms identified by GSEA analysis as being enriched in males and females respectively. (b) Oxygen consumption rate (OCR) was monitored to assess the mitochondrial respiration of male and female PT cells at baseline and after metabolic stress. To induce metabolic stress, the following sequence of drugs was injected: 1 $\mu$ M oligomycin, 0.3 $\mu$ M FCCP, 100mM 2-DG, 1mM Rot/AA. The OCR was monitored in male and female PT cells (n=3 donors/sex; n=6-8 replicates/donor). (c) The basal OCR (p<0.0001, u=48), ATP-linked respiration (p<0.0001, t=5.223, df=42), reserve capacity (p<0.0001, t=5.018, df=42) and maximal respiratory capacity (p<0.0001, t=5.281, df=42) of male and female PT cells were calculated from the OCR curves in panel B. Group-to-group differences were assessed using two-tailed unpaired T tests for variables following a normal distribution, and Mann-Whitney tests for variables with a non-parametric distribution. (d) In a separate experiment, the intracellular levels of ATP (p<0.0001, t=5.959, df=34), NAD (p=0.029, u=93),  $\beta$ -nicotinamide mononucleotide (p<0.0001, t=4.575, df=34), GTP (p<0.0001, t=7.45, df=34), ITP (p=0.0001, u=46), and UTP (p=0.0001, t=4.316, df=34) were determined in male and female PT cells (n=3 donors/sex; n=6 replicates/donor). Group-to-group differences were assessed using two-tailed unpaired T tests for variables following a normal distribution, and Mann-Whitney tests for variables with a non-parametric distribution. \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001; \*\*\*\*, p<0.0001. PT, proximal tubule; AUC, area under the curve; OCR, oxygen consumption rate; FCCP, p-trifluoromethoxy carbonyl cyanide phenyl hydrazone; 2-DG, 2-deoxyglucose; Rot, rotenone; AA: antimycin A; df: degrees of freedom.



**Figure 4. Identification and annotation of kidney immune cells.** (a) Compartment-specific analysis of 2491 immune cells comprising 12 clusters and (b) cell type markers used for cluster annotations (c) Heatmap of cell-type defining and highly expressed genes by each cluster separated by lymphoid and myeloid lineage. (d) UMAP plot showing the living donor myeloid cell data clustered together with the same three published datasets to define five cell states across datasets and their respective cluster markers. (e) UMAP plots highlighting the distribution of dataset membership across the cell states.



**Figure 5: Characterization of kidney-resident T and NK cells.** (a) NK cells ( $p=0.0025$ ,  $t=3.998$ ,  $df=10$ ) and NKT cells ( $p=0.0327$ ,  $t=2.476$ ,  $df=10$ ) are proportionally enriched in kidney relative to blood, while T cell ( $p=0.379$ ,  $t=0.918$ ,  $df=10$ ) abundance is unchanged. ( $n=6$ ) (b) Within the kidney T cell population, there is an enrichment of CD8<sup>+</sup> T cells ( $p=0.0060$ ,  $t=3.327$ ,  $df=12$ ) and a reduction in CD4<sup>+</sup> T cell ( $p=0.0025$ ,  $t=3.815$ ,  $df=12$ ) abundance with no change in TCRgd<sup>+</sup> T cells ( $p=0.2158$ ,  $u=14$ ) relative to blood. ( $n=6$ ) (c) Kidney T cells are predominantly antigen-experienced, marked by expression of CD45RO, while NK cells express minimal CD45RO. (d) Within kidney memory CD4<sup>+</sup> T cells, there is an enrichment in the Th1/17 subpopulation (CXCR3<sup>+</sup>CCR6<sup>+</sup>) ( $p=0.0238$ ,  $u=0$ ) and a reduction in Th2 subpopulation (CRTh2<sup>+</sup>) ( $p=0.0098$ ,  $t=3.513$ ,  $df=7$ ) abundance relative to blood while Th1 (CXCR3<sup>+</sup>) ( $p=0.3810$ ,  $u=5$ ) and Th17 (CCR6<sup>+</sup>) ( $p=0.5476$ ,  $u=6$ ) proportions were unchanged. ( $n=3$ ) (e) T cells expressing Granzyme K do not co-express perforin, indicating that they are a distinct T cell subset from Granzyme B<sup>+</sup>Perforin<sup>+</sup> cytotoxic T cells. (f) Violin plots showing differential gene expression of select markers in kidney T cells and NK cells relative to blood. (g) Surface levels of CD29 ( $p=0.0061$ ,  $t=3.869$ ,  $df=7$ ), CD49d ( $p=0.0027$ ,  $t=4.519$ ,  $df=7$ ) and CD69 ( $p=0.0203$ ,  $t=2.756$ ,  $df=10$ ) were higher on kidney T cells relative to blood as measured by flow cytometry, while CXCR4 ( $p=0.5887$ ,  $u=14$ ) was not ( $n=6$ ). (h) Surface levels of CD69 ( $p=0.0427$ ,  $t=2.321$ ,  $df=10$ ) was higher on kidney NK cells relative to blood while CD29 ( $p=0.6899$ ,  $t=0.4159$ ,  $df=7$ ), CD49d ( $p=0.9040$ ,  $t=0.1250$ ,  $df=7$ ), and CXCR4 ( $p=0.9326$ ,  $t=0.0868$ ,  $df=10$ ) were not. ( $n=6$ ) (i) CXCR6 abundance was higher at the protein level on both T cells ( $p=0.0086$ ,  $t=3.258$ ,  $df=10$ ) and NK cells ( $p=0.0364$ ,  $t=2.414$ ,  $df=10$ ) relative to blood. (j) Histograms showing no difference in CXCR4, increased CD69 and increased CXCR6 protein abundance in kidney T cells relative to blood. Group-to-group differences were assessed using two-tailed unpaired T tests for variables following a normal distribution, and Mann-Whitney tests for variables with a non-parametric distribution. , \* $p<0.05$ ; \*\* $p<0.01$ ; \*\*\* $p<0.001$ ; \*\*\*\* $p<0.0001$ .

635

## 636 **Materials and Methods**

### 637 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

#### 638 **Human Specimens**

639 Kidney tissue from tumour-unaffected nephrectomy specimens was used for initial method optimization.  
 640 Pre-implantation core biopsies were obtained from living donor kidneys after organ retrieval and flushing.  
 641 20 live donor kidney samples (10 male donors and 10 female donors) were processed for sequencing.  
 642 Additional living donor kidney samples were used in flow cytometry experiments for method optimization  
 643 and immunophenotyping. All experiments were conducted with institutional ethics approval from University  
 644 Health Network (CAPCR: 18-5914.0, Living donor; CAPCR: 18-5489.0, Tumour nephrectomy). Patient  
 645 demographic information for sequenced samples is summarized in **Supplementary Table 7**. All patients  
 646 provided informed written consent for inclusion in this study.

647

#### 648 **Murine Specimens**

649 Murine kidneys from C57BL/6 mice (AUP: 6156) were used for digestion optimization experiments.

650

### 651 **EXPERIMENTAL METHOD DETAILS**

#### 652 **Tissue digestion and CD45-enrichment**

653 All living donor samples used for sequencing were processed within one hour of organ retrieval. Briefly,  
 654 biopsies were collected in RPMI 1640 (Gibco, cat # 11875119) on ice, and mechanically dissociated with a  
 655 blade before enzymatic digestion at 37°C with 0.1 mg/ml DNase I (STEMCELL, cat # 07470), 3300 CDA  
 656 units/ml Collagenase MA (VitaCyte, cat # 001-2030) and 1430 NP units/ml BP neutral protease (VitaCyte, cat  
 657 # 003-1000) for 20 minutes at 37°C with intermittent agitation in an dissociation protocol optimized to  
 658 maximize viability and to preserve representation of rare and fragile cell populations (**Supplementary Fig.**  
 659 **15**). Cell suspensions were filtered through 35µm cell strainer snap-cap FACS tubes (Falcon, cat# 352235)  
 660 and a plunger from a 1ml syringe was used to gently mash remaining tissue in the strainer before rinsing  
 661 strainer lid with 1:1 volume of FBS (HyClone, cat # SH3039603PM) on ice. A low frequency (<1%) of immune

cells in the single cell suspension from a kidney biopsy core (**Fig. 1a**) necessitated immune enrichment in 10 samples (5 males, 5 females) using magnetic EasySep Human CD45 depletion kit II (STEMCELL, cat# 17898), as per the manufacturer's modified instructions for positive selection of CD45-expressing cells.

# **Single-cell RNA sequencing**

Samples were prepared according to 10X Genomics Single Cell 3' v3 Reagent kit user guide<sup>73</sup>. The pilot sequencing sample from nephrectomy tissue was sequenced using 10X Genomics Single Cell 5' v2 Reagents. Samples were washed twice in PBS (Life Technologies) plus 0.04% BSA, and viability was determined by a hemocytometer (Thermo Fisher) via Trypan Blue staining. Following counting, the appropriate volume for each sample was calculated for a target capture of 9,000 cells. For CD45-enriched samples, all cells were sequenced. Samples that were too low in cell concentration as defined by the user guide were washed, re-suspended in a reduced volume and counted again using a haemocytometer prior to loading onto the 10x single cell B chip. After droplet generation, samples were transferred onto a pre-chilled 96 well plate (Eppendorf), heat sealed and incubated overnight in a Veriti 96-well thermos cycler (Thermo Fisher). The next day, sample cDNA was recovered using Recovery Agent provided by 10x and subsequently cleaned up using a Silane DynaBead (Thermo Fisher) mix as outlined by the user guide. Purified cDNA was amplified for 11 cycles before being cleaned up using SPRIselect beads (Beckman). Samples were diluted 4:1 (elution buffer (Qiagen):cDNA) and run on a Bioanalyzer (Agilent Technologies) to determine cDNA concentration. cDNA libraries were prepared as outlined by the Single Cell 3' Reagent Kits v3 user guide with modifications to the PCR cycles based on the calculated cDNA concentration.

The molarity of each library was calculated based on library size as measured bioanalyzer (Agilent Technologies) and qPCR amplification data (Roche). Samples were pooled and normalized to 1.5 nM. Library pool was denatured using 0.2N NaOH (Sigma) for 8 minutes at room temperature, neutralized with 400mM Tris-HCL (Sigma). Library pool at a final concentration of 300pM were loaded to sequence on Novaseq 6000 (Illumina). Samples were sequenced with the following run parameters: Read 1-28 cycles, Read 2- 90, index 1-10 cycles, index 2-10 cycles. Across samples, cells were sequenced to a target depth of 40,000 reads per

cell. Mapping and quantification were performed using the 10X Genomics CellRanger pipeline version 3.1.0. Cell metric summaries for each sample in **Supplementary Table 8**.

### **Single-nucleus RNA sequencing**

A pilot single-nucleus RNA sequencing experiment was undertaken to compare single cell versus single nuclear results from a matched sample. The biopsy was collected fresh and divided into 8 segments, evenly distributed to be processed fresh for single cell RNA sequencing as above, and the remainder was flash frozen in liquid nitrogen. The sample was later retrieved from liquid nitrogen and processed on dry ice according to the protocol in<sup>74</sup> with a lysis buffer containing: 0.32 mM sucrose (BioShop SUC507.1), 5 mM CaCl<sub>2</sub> (VWR, 97062-820), 3 mM MgCl<sub>2</sub> (Thermo Fisher AM9530G), 20 mM Tris-HCl pH 7.5 (Thermo Fisher, 15567027), 0.1% TritonX-100 (Sigma Aldrich T8787-50ML), 0.1 mM EDTA pH 8.0 (Thermo Fisher AM9260G), 40 U/ml Protector RNase inhibitor (Sigma Aldrich 3335399001) in UltraPure DNase/RNase-free water (Thermo Fisher 10977015). The nuclei were captured and sequenced using 10X Genomics Single Cell 3' v3 Reagents as above.

### **Data quality control, clustering, differential expression, pathway analysis and cell-cell interaction inference**

Original study recruitment included samples from 20 donors, however, data from one male donor was poor quality and was excluded from downstream analysis. Thus, our final dataset consisted of 19 donors (10 female, 9 male), with 10 CD45-enriched samples (5 female, 5 male) and 9 samples not enriched for CD45<sup>+</sup> cells referred to as “total kidney” (5 female, 4 males). To preserve representation of rare cell types with uniquely expressed genes, we retained genes expressed in a minimum of 1 cell in the individual datasets.

Ambient RNA contamination was corrected using the AutoEst function in SoupX<sup>75</sup> (**Supplementary Fig. 16**). DoubletFinder<sup>76</sup> was used to identify and remove cells most likely to be doublets, rather than implementation of a maximum gene or feature threshold. For total samples, a high doublet rate threshold of 7.5% was applied (as utilized in comparable studies<sup>77</sup>), while for CD45-enriched samples, the doublet rate was calculated as 0.8% per 1000 cells captured, as per 10X Genomics estimated doublet rates<sup>73</sup>. The



individual datasets were then merged. Upon merging all of the individual datasets, the cells clustered according to cell type rather than donor/batch, and importantly, no batch correction of the data was required.

Cell type-specific thresholds were set to remove low quality cells. For immune cells (clusters expressing *PTPRC*), all cells with >10% of UMIs mapped to mitochondrial genes were removed, along with cells that had low transcript abundance (<1000) or gene diversity (<200 unique genes). Separately, prior to removing cells with low transcripts/features, data was mined for the presence of granulocyte lineage cells such as neutrophils which are often removed by typical QC thresholds due to high RNase activity and low gene content, however very few neutrophils (>20) were identified by marker expression in the raw data across all samples. For parenchymal cells, all cells with >40% of mitochondrial-mapped UMIs were removed; this high threshold was imposed due to known high mitochondrial content of proximal tubular cells<sup>78</sup>. Additionally, cells with low transcript abundance (<1000) and low gene diversity (<750 unique genes) were removed. Cells expressing hemoglobin genes (*HBB*, *HBA1/2*) (n=160) were removed. Following normalization (SCTransform<sup>79</sup>) and feature selection (M3Drop/DANB<sup>80</sup>), principal component analysis was used for dimensionality reduction (RunPCA) and cells were clustered using the Louvain algorithm with 30 principal components (FindNeighbors and FindClusters) (Seurat<sup>81</sup>). Clusters were visualized using UMAP algorithm<sup>82</sup>.

The dataset was divided into 3 broad subgroups identified as being Immune (*PTPRC*<sup>+</sup>) or Parenchymal (Proximal Tubular (expressing *CUBN*, *HNF4A*, *SLC34A1*, *LRP2*, *SLC17A1*) or non-Proximal Tubular) in origin. These subgroups were re-clustered and further annotated using a curated marker list (**Supplementary Table 6**). Cluster defining genes were identified by Seurat's FindMarkers<sup>81</sup>.

Ranked gene lists were generated using Wilcoxon rank sum testing from the presto package (wilcoxauc function)<sup>83</sup> were used as input for pathway analysis using GSEA<sup>84</sup>. Reference gene sets were acquired from the Bader lab repository ([http://download.baderlab.org/EM\\_Genesets/](http://download.baderlab.org/EM_Genesets/)) – Geneset used: (Human\_GOBP\_AllPathways\_no\_GO\_ia\_January\_13\_2021\_symbol.gmt.txt). To identify pathways enriched in immune cell clusters, the ranked gene lists were generated for each cluster comparing that cluster versus all other clusters.

741 Cell-cell communication was inferred from the sequencing data using LIANA which generates a  
742 consensus ranking across several methods<sup>85</sup>. The OmniPath interaction database was used<sup>86</sup> with the  
743 following methods for inferring interactions implemented through the package: SingleCellSignalR<sup>87</sup>, iTalk<sup>88</sup>,  
744 NATMI<sup>89</sup>, Connectome<sup>90</sup>, CellChat<sup>91</sup> and CellPhoneDB<sup>92</sup>. Results are summarized in Supplementary Table 5.  
745 Separately, SingleCellSignalR, NATMI, iTALK and Connectome methods were used to generate a consensus  
746 score using the CellPhoneDB database to infer interactions inclusive of multimeric complexes as accounted  
747 for in the CellPhoneDB interaction database, summarized in Supplementary Table 6.

748

#### 749 **Identification of innate lymphoid cells**

750 A predictive tool for cell type classification (scPred<sup>93</sup>) was trained on single-cell data generated from flow  
751 cytometry-sorted ILCs<sup>94</sup> and T cells<sup>95</sup>. Using this classifier, some cells present within our dataset were  
752 putatively identified as ILCs.

753

#### 754 **Transcription factor analysis**

755 Top cluster defining genes for PT5 and PT3, respectively were uploaded to CHEA3<sup>96</sup>  
756 (<https://maayanlab.cloud/chea3/>), and the top 10 predicted upstream regulators were identified.

757

#### 758 **Comparison of kidney immune cells to PBMCs**

759 To identify differences in gene expression between T cells and NK cells from peripheral blood versus kidney,  
760 PBMC data (GSE148665)<sup>47</sup> was integrated with the immune only kidney data using Harmony<sup>97</sup>. A second  
761 independent PBMC dataset<sup>48</sup>, was separately integrated with the kidney data for dataset-independent  
762 validation. NK cells and T cells (clusters expressing *NKG7* and/or *CD3E*) were compared using Seurat's  
763 FindAllMarkers function. Violin plots and volcano plots were created using Seurat and EnhancedVolcano<sup>98</sup>.

764

#### 765 **Comparison of Myeloid cells**

766 To identify differences in myeloid cell populations in living kidney donors compared to publicly available  
767 human kidney single-cell RNA sequencing datasets from tumour nephrectomy or deceased donor tissue



sources, CD68-expressing clusters from Stewart & Ferdinand *et al.*,<sup>3</sup> Zimmerman *et al.*,<sup>45</sup> and Argüello *et al.*<sup>46</sup> were scored using a random forest classifier (SingleCellNet<sup>99</sup>) to identify cells from the published datasets corresponding to the five myeloid clusters in the living donor data. Separately, all myeloid cells from this data and the three published studies were integrated and clustered to identify cell states using OCAT<sup>100</sup>. The datasets were also integrated and batch corrected using Seurat v3 integration (FindIntegrationAnchors and IntegrateData functions). The cell state identities from OCAT were mapped onto the integrated object and marker genes of cell states were identified using Seurat's FindAllMarkers function. Lineage analysis by pseudotime inference was applied to the OCAT-identified clustering of the combined myeloid populations using slingshot<sup>101</sup>, without indicating any clusters as either start or end points.

### **Sex differences analysis**

Principal component analysis (PCA) followed by Varimax rotation was performed on all major parenchymal and immune populations. Varimax-rotated principal components 2:25 were serially plotted against component 1, to identify whether a separation on the basis of sex was evident. If seen, the top 100 genes (50 from each end of the gene loading list) associated with the Varimax-rotated principal component were retained for further analysis.

Sex differences in proximal tubular cells were identified using sparse partial least squares discriminant analysis (sPLS-DA) in mixOmics<sup>102</sup>. Using the tuning function (tune.splsda), the optimal values for sparsity parameters were determined to be 1 component with 80 variables (genes). To test the classifier, the data were separated into a training dataset ( $\frac{2}{3}$  of cells sampled) and a query dataset (remaining  $\frac{1}{3}$ ). Next, our 80-gene signature was applied to an external dataset (Liao *et al.*<sup>20</sup>) for validation. Here, the entire living donor dataset was used as the training dataset and the external dataset was used as the query dataset. To determine the contribution of sex chromosome encoded genes to the model, all X- and Y-chromosome encoded genes were removed from the datasets prior to analysis, where the tuned parameters identified the optimal model to include 1 component with 15 variables. This 15-gene signature was also validated in the Liao *et al.* dataset. Hierarchical structure, zero inflation, and pseudoreplication bias in single-cell data pose specific challenges for differential expression analyses<sup>103-105</sup>. To circumvent these

limitations, we implemented a mixed effects model using MAST<sup>105,106</sup>. For differential expression testing between male and female proximal tubule cells, the dataset was filtered to include only genes which were expressed in each sample (9792 genes). Differential expression testing was conducted using MAST with a random effect for sample (zlm~ cellular detection rate + donor sex + (1| sampleID)). As this approach excluded genes expressed exclusively by one sex (e.g. Y chromosome encoded genes, and XIST), such genes were added to MAST differentially expressed genes (MAST+) for comparison with the results of the other methods (Varimax, sPLS-DA).

All significant genes returned using MAST analysis were subjected to enrichment analysis (GSEA<sup>84,107</sup>) using reference gene sets acquired from the Bader lab repository: ([http://download.baderlab.org/EM\\_Genesets/](http://download.baderlab.org/EM_Genesets/)); Geneset used: (Human\_GOBP\_AllPathways\_no\_GO\_ia\_January\_13\_2021\_symbol.gmt.txt).

## **Cryopreservation**

Cells from additional (non-sequenced) fresh living donor biopsies or cells remaining following 10X cell capture for sequencing were resuspended in 90% human serum (Sigma, cat# H4522) and 10% DMSO for cryopreservation and cooled to -80°C in a Mr.Frosty (Sigma, cat #C1562), then transferred to liquid nitrogen for long term storage.

## **Flow Cytometry**

After fresh tissue digestion, cells were washed in PBS + 2% FCS before staining. Cryopreserved cells were thawed and washed twice in PBS + 2% FCS. Cells were incubated at 4°C for 15 minutes with an Fc receptor blocker (BioLegend TruStain FcX, cat # 422302) according to manufacturer instructions before cocktails of surface antibodies were added for 30 minutes at 4°C. If intracellular targets/transcription factors were included in the panel, cells were resuspended in FOXP3 transcription factor fix perm buffer (eBio, cat # 00-5523-00) and stained with intracellular antibodies in 1X permeabilization buffer (eBio, cat # 00-8333-56). If no intracellular targets were included in the staining panel, cells were fixed in 2% PFA (Thermo Scientific, cat # J19443) after surface staining.

822 Cells were stained with the following surface antibodies: Anti-human CD8a FITC (1:100, clone RPA-  
823 T8, BioLegend, cat # 301050), Anti-human TCRgd FITC (1:100, clone B1, BioLegend, cat # 331208), Anti-  
824 human CD3 FITC (1:100, clone UCHT1, BioLegend, cat # 300440), Anti-human CD8a PerCP (1:50, clone RPA-  
825 T8, BioLegend, cat # 301030), Anti-human CXCR6 PerCP Cy5.5 (1:50, clone K041E5, BioLegend, cat #  
826 356010), Anti-human CCR8 PE (1:100, clone L263G8, BioLegend, cat # 360604), Anti-human CD127 PE (1:50,  
827 clone hIL-7R-M21, BD Biosciences, cat # 557938), Anti-human CD15 PE (1:100, clone W6D3, BD Biosciences,  
828 cat # 562371), Anti-human CD163 PE (1:50, clone GHI/61, BioLegend, cat # 333606), Anti-human CD49d PE  
829 Dazzle 594 (1:100, clone 9F10, BioLegend, cat # 304325), Anti-human CRTh2 PE Dazzle 594 (1:50, clone  
830 BM16, BioLegend, cat # 350126), Anti-human CD31 PE Dazzle 594 (1:100, clone WM59, BioLegend, cat #  
831 303130), Anti-human CD16 PE Dazzle 594 (1:100, clone 3G8, BioLegend, cat # 302054), Anti-human CD45 PE-  
832 CF594 (1:100, clone HI30, BD Biosciences, cat # 562279), Anti-human CD29 PE Cy7 (1:100, clone TS2/16,  
833 BioLegend, cat # 303025), Anti-human CD45RO PE Cy7 (1:50, clone UCHL1, BD Biosciences, cat # 560608),  
834 Anti-human MerTK PE Cy7 (1:50, clone 590H11G1E3, BioLegend, cat # 367610), Anti-human TIGIT PE Cy 7  
835 (1:50, clone MBSA43, Invitrogen, cat # 25-9500-42), Anti-human CD94 APC (1:100, clone HP-3D9,  
836 eBioscience, cat # 17-5094-42), Anti-human CCR6 APC (1:25, clone G034E3, BioLegend, cat # 353416), Anti-  
837 human CD206 APC (1:50, clone 15-2, BioLegend, cat # 321110), Anti-human CD4 Alexa700 (1:50, clone RPA-  
838 T4, eBioscience, cat # 56-0049-42), Anti-human CD127 Alexa700 (1:50, clone eBioRDR5, eBioscience, cat #  
839 56-1278-42), Anti-human CXCR4 APC Cy7 (1:50, clone 12G5, BioLegend, cat # 306528), Anti-human CTLA4  
840 APC Cy7 (1:25, clone BNI3, BioLegend, cat # 369634), Anti-human CD56 APC Cy7 (1:50, clone HCD56,  
841 BioLegend, cat # 318332), Anti-human CD45 APC Cy7 (1:100, clone HI30, BioLegend, cat # 304014), Anti-  
842 human CD14 APC eF780 (1:100, clone 61D3, eBioscience, cat # 47-0149-42), Anti-human CXCR3 BV421 (1:50,  
843 clone G025H7, BioLegend, cat # 353716), Anti-human CD13 BV421 (1:50, clone WM15, BioLegend, cat #  
844 301716), Anti-human TCRgd BV510 (1:100, clone B1, BioLegend, cat # 331220), Anti-human TCRab BV510  
845 (1:100, clone IP26, BioLegend, cat # 306734), Anti-human CD5 BV510 (1:100, clone L17F12, BioLegend, cat #  
846 364018), Anti-human FcER1 BV510 (1:100, clone AER-37, BioLegend, cat # 334626), Anti-human CD303  
847 BV510 (1:100, clone 201A, BioLegend, cat # 354232), Anti-human CD123 BV510 (1:100, clone 6H6,  
848 BioLegend, cat # 306022), Anti-human CD34 BV510 (1:100, clone 581, BioLegend, cat #343528), Anti-human

849 CD20 BV510 (1:100, clone 2H7, BioLegend, cat # 302340), Anti-human CD3 BV510 (1:100, clone OKT3,  
850 BioLegend, cat # 317332), Anti-human CD14 BV510 (1:100, clone M5E2, BioLegend, cat # 301842), Anti-  
851 human CD19 BV510 (1:100, clone HIB19, BioLegend, cat # 302242), Anti-human CD4 BV510 (1:100, clone  
852 RPA-T4, BioLegend, cat # 300546), Anti-human CD56 BV605 (1:50, clone HCD56, BioLegend, cat # 318334),  
853 Anti-human CD69 BV650 (1:100, clone FN50, BioLegend, cat # 310934), Anti-human CD8a BV650 (1:50, clone  
854 RPA-T8, BioLegend, cat # 301042), Anti-human CD326 BV650 (1:100, clone 9C4, BioLegend, cat # 324226),  
855 Anti-human CD107a BV750 (1:50, clone H4A3, BioLegend, cat # 328638), Anti-human CD103 BV711 (1:100,  
856 clone Ber-ACT8, BioLegend, cat # 350222), Anti-human CD10 BV711 (1:100, clone HI10a, BioLegend, cat #  
857 312226), Anti-human CD45 BV711 (1:100, clone HI30, BioLegend, cat # 304050), Anti-human CD3 BV785  
858 (1:100, clone OKT3, BioLegend, cat # 317330), Anti-human HLA-DR BV785 (1:50, clone L243, BioLegend, cat #  
859 307642), Anti-human PD-1 BV785 (1:50, clone EH12.2H7, BioLegend, cat # 329930), Anti-human CD45  
860 BUV395 (1:100, clone HI30, BD Biosciences, cat # 563792), Anti-human CD16 BUV395 (1:100, clone 3G8, BD  
861 Biosciences, cat # 563785), Anti-human CD3 BUV395 (1:100, clone UCHT1, BD Biosciences, cat # 563546),  
862 Anti-human CD69 BUV496 (1:50, clone FN50, BD Biosciences, cat # 750214), Anti-human CD16 BUV737  
863 (1:100, clone 3G8, BD Biosciences, cat # 564434). The following antibodies were used for intracellular  
864 staining: Anti-human TBET FITC (1:50, clone 4B10, BioLegend, cat # 644812), Anti-human Granzyme B FITC  
865 (1:100, clone QA16A02, BioLegend, cat # 372206), Anti-human Granzyme K PE (1:25, clone GM26E7,  
866 BioLegend, cat # 370512), Anti-human FOXP3 PE CF594 (1:25, clone 236A/E7, BD Biosciences, cat # 563955),  
867 Anti-human GATA3 PE CF594 (1:25, clone L50-823, BD Bioscience, cat # 563510), Anti-human Amphiregulin  
868 PE Cy 7 (1:25, clone AREG559, Invitrogen, cat # 25-5370-42), Anti-mouse Nur77 APC (1:25, clone REA704,  
869 Miltenyi, cat # 130-111-231), Anti-human EOMES APC eF780 (1:25, clone WD1928, eBioscience, cat #47-  
870 4877-42), Anti-human RORgT BV650 (1:50, clone Q21-559, BD Biosciences, cat # 563424), Anti-human  
871 Perforin eF450 (1:100, clone dG9, Invitrogen, cat # 48-9994-42). Cells were analyzed on a BD LSR Fortessa  
872 flow cytometer. Data were plotted using FlowJo v10.7.1 (TreeStar) and Prism (Graphpad, v9).

873

874 **PT cell culture**

875 Commercially available human primary PTs from 6 donors (3 males and 3 females, Lonza Walkersville Inc)  
876 were expanded at passage 4, and studied at passage 5. The main donor characteristics are summarized in  
877 Supplementary Table 2. Cells were grown in custom-made Dulbecco's modified Eagle's medium (DMEM)  
878 containing 5.55mM D-glucose, 4mM L-glutamine, and 1mM sodium pyruvate, and supplemented with  
879 10ng/mL human EGF, 0.05M hydrocortisone, 1x of Transferrin/Insulin/Selenium (Invitrogen), 10% v/v dialyzed  
880 fetal bovine serum (FBS), 50g/mL streptomycin, and 50units/mL penicillin, as previously<sup>108,109</sup>. Cells were  
881 serum-starved for 24h prior to collection for gene expression, metabolite measurements, and assessment of  
882 metabolic function. For gene expression experiments, cells were washed with PBS, harvested with trypsin,  
883 and snap-frozen at -80°C until further analysis.

884

# **885 Assessment of metabolic function in human primary PT cells**

886 Mitochondrial respiration was assessed in male and female PTECs by measuring their oxygen consumption  
887 rate (OCR) in a Seahorse XFe96 analyzer (Agilent). Glycolysis was also assessed by monitoring the extracellular  
888 acidification rate (ECAR). Upon 80-90% confluence, cells were detached with 0.25% trypsin (5min, 37°C),  
889 counted and seeded in a Seahorse XFe96 Cell Culture Microplate at a density of 15,000 cells/well in 100μL of  
890 DMEM complete media. After adhering for 6h, PT cells were exposed to serum starvation conditions for 24h.  
891 One hour prior to the metabolic function assay, cells were washed with phenol-free basal media (Agilent) and  
892 exposed to 150μL of assay media, which included 2mM glutamine and 5.55mM glucose. During the assay, OCR  
893 and ECAR were recorded at baseline and after metabolic stress. To induce metabolic stress, 25μL of  
894 oligomycin, p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP), 2-deoxyglucose (2-DG), and  
895 Rotenone + Antimycin A (Rot+AA) were sequentially injected into the microplate wells. After optimization,  
896 the following working concentrations were established for each drug: oligomycin: 1μM; FCCP: 0.3μM, 2-DG:  
897 100mM; Rot: 1μM; AA: 1μM. Basal respiration, ATP-linked respiration, maximal respiratory capacity, and  
898 reserve capacity were assessed by calculating the area under the curve (AUC) from OCR curves (**Fig. 3b, c**).  
899 Basal glycolysis, maximal glycolytic capacity, and glycolytic reserve were determined by calculating the AUC  
900 from ECAR curves (**Supplementary Fig. 6**).

901

902 **Cell metabolite measurements**

903 *Sample preparation*

904 Male and female primary PTs were grown on 6-well plates and subjected to starvation as described above.

905 The levels of intracellular metabolites were then determined using liquid chromatography-mass

906 spectrometry. After collecting the supernatant, 1mL of extraction solvent (80:20 mixture of methanol:water)

907 was added into each well, in order to extract intracellular metabolites. Plates were placed on dry ice. The

908 adherent material was then triturated, collected into Eppendorf tubes, and stored at -80°C. Cell lysate

909 collection was followed by 3 freeze-thawing cycles in dry ice (to shift sample temperature between -80°C and

910 -20°C). The insoluble material from each sample was then precipitated by centrifugation at full speed for 5min.

911 The resulting pellet was dried at room temperature and used for total RNA quantification using the Quant-iT

912 Ribogreen assay (Invitrogen). In turn, the metabolite extract was dried under high purity nitrogen gas

913 (turbovap) and resuspended with appropriate volume of buffer (0.5µL of LC-MS grade water to 1µg of RNA)

914 based on total RNA levels. The appropriate volumes of heavy-labelled (<sup>13</sup>C/<sup>15</sup>N) reference metabolites were

915 spiked into each reconstituted sample for quantitation. The heavy-labelled metabolites used as internal

916 reference standards were acquired in as a metabolite extract from yeast that had been 99% labelled with <sup>13</sup>C-

917 glucose and <sup>15</sup>N-ammonia. To determine background metabolite signals, a mock plate without cells and equal

918 volume of media was processed in parallel to the study plates.

919

920 *Liquid chromatography-mass spectrometry (LC-MS)*

921 Cellular metabolites were measured by injecting 2µL of sample in full scan MS1 mode using an Agilent 6550

922 qToF mass spectrometer coupled to an Agilent 1290 binary pump UPLC system. Most polar metabolite

923 analytes presented here were measured using an Agilent ZORBAX ExtendC18 1.8 µm, 2.1 mm X 150 mm

924 reverse phase chromatography using tributylamine as an ion paring agent as previously described<sup>110</sup>. The

925 Agilent 6550 qToF was fitted with a dual AJS ESI source and an iFunnel with a gas temperature set to 150°C

926 at 14L/min and 45psig. Sheath gas temperature was set to 325°C at 12L/min. Capillary and nozzle voltages

927 were set to 2000V. Funnel conditions were changed from default to -30V DC, high pressure funnel drop -100V

928 and RF voltage of 110V, low pressure funnel drop -50V and RF voltage of 60V. Metabolite annotation in full

scan data was achieved by matching exact mass and retention time to an in-house database. The retention time and exact mass database were prepared by analyzing a collection of neat standards using the chromatographic method described above and confirming retention times by MS/MS fragmentation of neat standards.

### *Metabolite data analysis*

Metabolite raw data was extracted directly from .d folders and integrated in profile mode using an R-based software package developed by the Rosebrock Lab; ChromXtractorPro (personal correspondence K. Lavery and A. Rosebrock, adam.rosebrock@stonybrook.edu). The metabolites whose intensity in all the study samples fell at or below their intensity in the blank (consisting of resuspension buffer only) were excluded from further analyses. Next, the integrated light (L) intensity of each metabolite was normalized to the intensity of its internal heavy (H) standard. The L/H ratio minimized the potential stochastic variation in the signal produced by the instrument due to changes in humidity and/or temperature, enabling the relative quantitation and comparative analysis of each metabolite. The analysis enabled the detection of 158 intracellular metabolites<sup>111</sup>. Data corresponding to the intracellular levels of NAD,  $\beta$ -nicotinamide mononucleotide, ATP, GTP, ITP, UTP were interrogated.

### **Gene expression validation studies**

RNA was extracted from the cell pellets of human primary male and female PT cells using the RNAeasy Mini Kit (Qiagen). After quantifying RNA concentration in a Nanodrop instrument (Thermo), 300-700ng of RNA were retrotranscribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Male and female PTs had been grown and serum-starved as above. In these cells, gene levels of *KDM5D*, *UTY*, *EIF1AY*, *EIF1AX*, *DDX3X*, *MT1F*, *MT1G*, and *MT1H* were measured by real-time quantitative PCR using a Power SYBR<sup>®</sup> Green PCR Master Mix reagent (Applied Biosystems) and normalized to RPL31. The fluorescent signal was measured in a LightCycler<sup>®</sup> 480 Instrument II (Roche). All primer sequences employed in this study are summarized in **Supplementary Table 10**.



956

## 957 **Quantification and statistical analysis**

958 Statistical tests were conducted within R and using GraphPad Prism 9 software. For all comparisons, normality  
959 was determined using a Shapiro-Wilk test. Group-to-group differences were assessed using two-tailed  
960 unpaired T tests for variables following a normal distribution, and Mann-Whitney tests for variables with a  
961 non-parametric distribution. All p values below 0.05 were considered significant. Significance level for each  
962 test is indicated in the figures. For each experiment, n is reported in the figure legends and represents the  
963 number of samples.

964

## 965 **Data availability**

966 Count matrices from our complete data object are being submitted to NCBI GEO, and will be made publicly  
967 available upon publication. Additional information and data are available from the authors upon reasonable  
968 request, and in line with University Health Network (UHN) and UHN Research Ethics Board policies.

969

## 970 **Code availability**

971 We are preparing a Github repository for the custom scripts generated for data analysis.

972

## 973 **Methods References**

- 974 73.  
975 [https://assets.ctfassets.net/an68im79xiti/4tjk4KvXzTWgTs8f3tvUjq/2259891d68c53693e75](https://assets.ctfassets.net/an68im79xiti/4tjk4KvXzTWgTs8f3tvUjq/2259891d68c53693e753e1b45e42de2d/CG000183_ChromiumSingleCell3__v3_UG_Rev_C.pdf)  
976 [3e1b45e42de2d/CG000183\\_ChromiumSingleCell3\\_\\_v3\\_UG\\_Rev\\_C.pdf](https://assets.ctfassets.net/an68im79xiti/4tjk4KvXzTWgTs8f3tvUjq/2259891d68c53693e753e1b45e42de2d/CG000183_ChromiumSingleCell3__v3_UG_Rev_C.pdf). 2021. (Accessed  
977 03/05/2021, at  
978 [https://assets.ctfassets.net/an68im79xiti/4tjk4KvXzTWgTs8f3tvUjq/2259891d68c53693e753e1b45](https://assets.ctfassets.net/an68im79xiti/4tjk4KvXzTWgTs8f3tvUjq/2259891d68c53693e753e1b45e42de2d/CG000183_ChromiumSingleCell3__v3_UG_Rev_C.pdf)  
979 [e42de2d/CG000183\\_ChromiumSingleCell3\\_\\_v3\\_UG\\_Rev\\_C.pdf](https://assets.ctfassets.net/an68im79xiti/4tjk4KvXzTWgTs8f3tvUjq/2259891d68c53693e753e1b45e42de2d/CG000183_ChromiumSingleCell3__v3_UG_Rev_C.pdf).)  
980 74. Slyper M, Porter CBM, Ashenberg O, et al. A single-cell and single-nucleus RNA-Seq toolbox  
981 for fresh and frozen human tumors. Nat Med 2020;26:792-802.  
982 75. Young MD, Behjati S. SoupX removes ambient RNA contamination from droplet-based  
983 single-cell RNA sequencing data. Gigascience 2020;9.  
984 76. McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet Detection in Single-Cell RNA  
985 Sequencing Data Using Artificial Nearest Neighbors. Cell Syst 2019;8:329-37 e4.  
986 77. Park J, Shrestha R, Qiu C, et al. Single-cell transcriptomics of the mouse kidney reveals  
987 potential cellular targets of kidney disease. Science 2018;360:758-63.  
988 78. Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates  
989 complex I disease biology. Cell 2008;134:112-23.



990 79. Hafemeister C, Satija R. Normalization and variance stabilization of single-cell RNA-seq data  
991 using regularized negative binomial regression. *Genome Biol* 2019;20:296.

992 80. Andrews TS, Hemberg M. M3Drop: dropout-based feature selection for scRNASeq.  
993 *Bioinformatics* 2019;35:2865-7.

994 81. Stuart T, Butler A, Hoffman P, et al. Comprehensive Integration of Single-Cell Data. *Cell*  
995 2019;177:1888-902 e21.

996 82. Becht E, McInnes L, Healy J, et al. Dimensionality reduction for visualizing single-cell data  
997 using UMAP. *Nat Biotechnol* 2018.

998 83. . (Accessed 03/05/2021, at <https://github.com/immunogenomics/presto>.)

999 84. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-  
1000 based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*  
1001 2005;102:15545-50.

1002 85. Daniel Dimitrov DT, Charlotte Boys, James Nagai, Ricardo Ramirez Flores, Hyojin Kim, Bence  
1003 Szalai, Ivan Costa, Aurelien Dugourd, Alberto Valdeolivas, Julio Saez Rodriguez. Cell-cell  
1004 Communication Inference from Single-cell RNA-Seq Data: a Comparison of Methods and Resources.  
1005 Research Square 2021.

1006 86. Turei D, Valdeolivas A, Gul L, et al. Integrated intra- and intercellular signaling knowledge for  
1007 multicellular omics analysis. *Mol Syst Biol* 2021;17:e9923.

1008 87. Cabello-Aguilar S, Alame M, Kon-Sun-Tack F, Fau C, Lacroix M, Colinge J. SingleCellSignalR:  
1009 inference of intercellular networks from single-cell transcriptomics. *Nucleic Acids Res* 2020;48:e55.

1010 88. Wang Y WR, Zhang S, Song S, Jiang C, Han G, Wang M, Ajani J, Futreal A, Wang L. iTALK: an  
1011 R Package to Characterize and Illustrate Intercellular Communication. *BioRxiv* 2019.

1012 89. Hou R, Denisenko E, Ong HT, Ramilowski JA, Forrest ARR. Predicting cell-to-cell  
1013 communication networks using NATMI. *Nat Commun* 2020;11:5011.

1014 90. Raredon MSB, Junchen Yang, James Garritano, Meng Wang, Dan Kushnir, Jonas Christian  
1015 Schupp, Taylor S. Adams, Allison M. Greaney, Katherine L. Leiby, Naftali Kaminski, Yuval Kluger,  
1016 Andre Levchenko, Laura E. Niklason. Connectome: computation and visualization of cell-cell  
1017 signaling topologies in single-cell systems data. *bioRxiv* 2021.

1018 91. Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication  
1019 using CellChat. *Nat Commun* 2021;12:1088.

1020 92. Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell-  
1021 cell communication from combined expression of multi-subunit ligand-receptor complexes. *Nat*  
1022 *Protoc* 2020;15:1484-506.

1023 93. Alquicira-Hernandez J, Sathe A, Ji HP, Nguyen Q, Powell JE. scPred: accurate supervised  
1024 method for cell-type classification from single-cell RNA-seq data. *Genome Biol* 2019;20:264.

1025 94. Bernink JH, Ohne Y, Teunissen MBM, et al. c-Kit-positive ILC2s exhibit an ILC3-like signature  
1026 that may contribute to IL-17-mediated pathologies. *Nat Immunol* 2019;20:992-1003.

1027 95. [https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.1.0/t\\_4k](https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.1.0/t_4k). 2017. at  
1028 [https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.1.0/t\\_4k](https://support.10xgenomics.com/single-cell-gene-expression/datasets/2.1.0/t_4k).)

1029 96. Keenan AB, Torre D, Lachmann A, et al. ChEA3: transcription factor enrichment analysis by  
1030 orthogonal omics integration. *Nucleic Acids Res* 2019;47:W212-W24.

1031 97. Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single-cell data  
1032 with Harmony. *Nat Methods* 2019;16:1289-96.

1033 98. Blighe K RS, Lewis M EnhancedVolcano: Publication-ready volcano plots with enhanced  
1034 colouring and labeling. <https://github.com/kevinblighe/EnhancedVolcano>.2020.

1035 99. Tan Y, Cahan P. SingleCellNet: A Computational Tool to Classify Single Cell RNA-Seq Data  
1036 Across Platforms and Across Species. *Cell Syst* 2019;9:207-13 e2.

1037 100. Wang C, Zhang L, Wang B. One Cell At a Time: A Unified Framework to Integrate and  
1038 Analyze Single-cell RNA-seq Data. *bioRxiv* 2021:2021.05.12.443814.

1039 101. Street K, Risso D, Fletcher RB, et al. Slingshot: cell lineage and pseudotime inference for  
1040 single-cell transcriptomics. BMC Genomics 2018;19:477.

1041 102. Rohart F, Gautier B, Singh A, Le Cao KA. mixOmics: An R package for 'omics feature selection  
1042 and multiple data integration. PLoS Comput Biol 2017;13:e1005752.

1043 103. Sonesson C, Robinson MD. Bias, robustness and scalability in single-cell differential  
1044 expression analysis. Nat Methods 2018;15:255-61.

1045 104. Wang T, Li B, Nelson CE, Nabavi S. Comparative analysis of differential gene expression  
1046 analysis tools for single-cell RNA sequencing data. BMC Bioinformatics 2019;20:40.

1047 105. Zimmerman KD, Espeland MA, Langefeld CD. A practical solution to pseudoreplication bias  
1048 in single-cell studies. Nat Commun 2021;12:738.

1049 106. Finak G, McDavid A, Yajima M, et al. MAST: a flexible statistical framework for assessing  
1050 transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data.  
1051 Genome Biol 2015;16:278.

1052 107. Reimand J, Isserlin R, Voisin V, et al. Pathway enrichment analysis and visualization of omics  
1053 data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc 2019;14:482-517.

1054 108. Konvalinka A, Zhou J, Dimitromanolakis A, et al. Determination of an angiotensin II-  
1055 regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell  
1056 culture (SILAC). J Biol Chem 2013;288:24834-47.

1057 109. Clotet-Freixas S, McEvoy CM, Batruch I, et al. Extracellular Matrix Injury of Kidney Allografts  
1058 in Antibody-Mediated Rejection: A Proteomics Study. J Am Soc Nephrol 2020;31:2705-24.

1059 110. Wan LC, Mao DY, Neculai D, et al. Reconstitution and characterization of eukaryotic N6-  
1060 threonylcarbamoylation of tRNA using a minimal enzyme system. Nucleic Acids Res 2013;41:6332-  
1061 46.

1062 111. Clotet-Freixas S.; Zaslaver, O.; Pastrello, C.; Kotlyar, M.; McEvoy, C.M.; Farkona, S.; Saha, A.;  
1063 Boshart, A.; Chan, S.; Riera, M.; Soler, M.J.; Isenbrandt, A.; Lamontagne-Proulx, J. ; Pradeloux, S.;  
1064 Coulombe, K.; Soulet, D.; Dart, A.B.; Wicklow, B.; McGavock, J.M. ;Blydt-Hansen, T.D.; Jurisica, I.;  
1065 Woo, M. ; Scholey, J.W. ; Röst, H.; Konvalinka, A. Cell Sex and Sex Hormones Modulate Kidney  
1066 Glucose and Glutamine Metabolism in Health and Diabetes. BioRxiv 2021.

## Supplementary Data

**Authors:** Caitriona M. McEvoy<sup>†1,2,3</sup>, Julia M. Murphy<sup>†1,2,4</sup>, Lin Zhang<sup>5</sup>, Sergi Clotet-Freixas<sup>^1,2</sup>, Jessica A. Mathews<sup>^1,2</sup>, James An<sup>1,2,4</sup>, Mehran Karimzadeh<sup>6</sup>, Delaram Pouyababar<sup>7,8</sup>, Shenghui Su<sup>1,2</sup>, Olga Zaslaver<sup>7,8</sup>, Hannes Röst<sup>7,8</sup>, Madhurangi Arambewela<sup>1,2</sup>, Lewis Y. Liu<sup>1,2,4</sup>, Sally Zhang<sup>12</sup>, Keith A. Lawson<sup>12</sup>, Antonio Finelli<sup>12</sup>, Bo Wang<sup>6,9,10,11</sup>, Sonya A. MacParland<sup>1,2,4,10</sup>, Gary D. Bader<sup>7,8,12,13</sup>, Ana Konvalinka<sup>\*,1,2,3,10,14</sup>, Sarah Q. Crome<sup>\*,1,2,4</sup>

### Affiliations:

<sup>1</sup>Toronto General Hospital Research Institute, University Health Network; Toronto, ON, Canada.

<sup>2</sup>Ajmera Transplant Centre, University Health Network; Toronto, ON, Canada.

<sup>3</sup>Department of Medicine, Division of Nephrology, University Health Network; Toronto, ON, Canada.

<sup>4</sup>Department of Immunology, University of Toronto; Toronto, ON, Canada.

<sup>5</sup>Department of Statistical Sciences, University of Toronto; Toronto, ON, Canada.

<sup>6</sup>Vector Institute; Toronto, ON, Canada.

<sup>7</sup>Department of Molecular Genetics, University of Toronto; Toronto, ON, Canada.

<sup>8</sup>The Donnelly Centre, University of Toronto; Toronto, ON, Canada.

<sup>9</sup>Department of Computer Science, University of Toronto; Toronto, ON, Canada.

<sup>10</sup>Department of Laboratory Medicine and Pathobiology, University of Toronto; Toronto, ON, Canada.

<sup>11</sup>Peter Munk Cardiac Centre, University Health Network; Toronto, ON, Canada.

<sup>12</sup>Princess Margaret Cancer Centre, University Health Network; Toronto, ON, Canada

<sup>13</sup>The Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Toronto, ON, Canada

<sup>14</sup>Institute of Medical Science, University of Toronto; Toronto, ON, Canada.

† co-first authorship

\* co-corresponding authorship

^ equal contribution

### \*co-corresponding authors:

Sarah Q. Crome ([sarah.crome@utoronto.ca](mailto:sarah.crome@utoronto.ca))

Ana Konvalinka ([Ana.Konvalinka@uhn.ca](mailto:Ana.Konvalinka@uhn.ca))

**Supplementary Tables**

A total of 10 supplementary tables are prepared for this manuscript. As some of the individual tables are large and not in a format that can be easily incorporated into the manuscript, they are not included with the pre-print PDF. If of interest, please reach out to corresponding authors to discuss.

**Supplementary Tables**

**Supplementary Table 1.** ST1-Results of sex analyses. Results of genes identified with Varimax rotated PCA, sPLS-DA, and differential gene expression analysis using MAST comparing male and female proximal tubular cells.

**Supplementary Table 2.** ST2-Primary PT donor characteristics. Characteristics of the donors from which primary proximal tubular epithelial cells were isolated for metabolic studies.

**Supplementary Table 3.** ST3-GSEA significant results. Summary of significant gene set enrichment analysis terms between male and female proximal tubular cells.

**Supplementary Table 4.** ST4- DEGs LD NK & T cells Vs PBMC. Results of differential gene expression analysis using Seurat comparing kidney NK and T lymphocytes to circulating lymphocytes from two studies.

**Supplementary Table 5.** ST5-Cell cell interactions Omnipath. Results of aggregate cell cell communication inference with consensus and individual scores across methods, with Omnipath used as the reference interaction database


**Supplementary Table 6.** ST5-Cell cell interactions with complexes CellPhoneDB. Results of aggregate cell cell communication inference with consensus and individual scores across methods, with CellPhoneDB used as the reference interaction database

**Supplementary Table 7.** ST7-Patient characteristics. Characteristics of the study population.


**Supplementary Table 8.** ST8- CellRanger summaries of sequenced samples. CellRanger summaries with sample metrics for each sequenced sample.

**Supplementary Table 9.** ST9- Curated cell annotation file. Curated marker gene list for cell type annotations.

**Supplementary Table 10.** ST10- qPCR sequences. Primer sequences used for qPCR validation of sex differences in PT cells.




**Supplementary Figure 1:** Additional proportion plots of total kidney dataset. (a) Clustering of total combined dataset of 27677 cells results in 23 clusters (b) Individual sample contribution to clustering, demonstrating that clusters are comprised of cells captured from multiple donors and in most cases all 19 samples contribute to each cluster. (c) Cell cycle assignment of clusters, with no exceptional variability in cell cycle state across clusters. (d) Distribution of sample preparation method (total homogenate versus CD45-positive magnetic bead enrichment) across clusters. (e) Distribution of donor sex across clusters.




**Supplementary Figure 2. Heterogeneity within Proximal Tubular (PT) dataset.** (a) Subclustering of PT dataset yielded 6 clusters; PT6 is predominantly composed of cells from one donor: "Total6". (b) Distribution of sample preparation method, sex, and donor identity across the PT dataset; PT4 is composed of cells from CD45-enriched samples. (c) Stacked violin plots showing enrichment of dissociation stress markers in PT3. (d-f) Stacked violin plots showing markers of the 'scattered tubular cell' and 'failed PT repair' population enriched in PT5(d), PT3(e), and both PT3 and PT5(f). (g) Transcription factor analysis using CHEA3, which illustrates the top 10 transcription factors predicted to regulate PT3, and separately, PT5 genes.






**Supplementary Figure 3. Heterogeneity in CTAL and Endothelial cell populations.** (a) 5 CTAL clusters and 4 endothelial clusters were identified. (b) Heatmap depicting expression of the marker genes of CTAL1-5. (c) CTAL2 and 4 are each chiefly comprised of cells from one donor (Total9 and CD45\_9, respectively). Selected marker genes of *CLDN10*-enriched CTAL1 (d) and *CLDN16*-enriched CTAL3 (e) populations, respectively. (f) Bubble plot showing enrichment for specific endothelial cell markers in all subpopulations; expression of peritubular capillary markers (*PLVAP*, *TMEM88*, *DNASE1L3*) in Endo1 and Endo3 respectively; expression of afferent arteriole and vasa recta genes (*SOX17*, *SERPINE2*, *CLDN5*, *CXCL12* and reduced *KDR*) in Endo2; and expression of glomerular microvascular endothelial cell markers in Endo4 (*EDH3*, *SOST* and *TBX3*). (g) Increased expression of extracellular matrix genes seen in Endo2 (characterised as afferent arterioles and vasa recta). Of the two peritubular populations described (Endo1 and Endo3), Endo3 is shown to have higher expression of vasodilators (*PTGIS* and *NOS3*) than Endo1. Endo4 illustrates expression of *GJA5* and *PTGIS*.






**Supplementary Figure 4. Varimax PCA and sparse partial least squares discriminant analysis (sPLS-DA) identifies sex differences in proximal tubular (PT) epithelial cells. (a)** Top 100 genes (50 from each end of the component) associated with varimax-rotated principal component 12 which revealed sex differences in proximal tubule cells. **(b)** Plot of 80 genes that were selected as variables in the sPLS-DA classifier (Model 1) from all detected genes. **(c)** Receiver operating characteristic (ROC) curve from Model 1 predict male and female sex with accuracy of 98%. **(d)** Plot of 15 genes in Model 2 (using all detected genes except those encoded on X or Y chromosomes as input) where 15 genes were selected as variables in the classifier. **(e)** ROC curve from Model 2. **(f)** Barplot of classification accuracy using Model 1 versus Model 2 to classify PT cells of the living donor data and of a validation dataset from Liao *et al.*<sup>20</sup>



**Supplementary Figure 5. Comparison of single nucleus RNA sequencing and single cell RNA sequencing.** (a) Data integration from a pilot sequencing experiment in which a single biopsy was divided and subjected to scRNAseq and single nucleus RNAseq (snRNAseq). From the integrated data, PT cell clusters were identified and analyzed. (b) Expression of PT cell marker genes used to identify clusters of PT cells in the integrated datasets. (c) Comparison of select genes from scRNAseq and snRNAseq reveals that several key genes exhibiting dichotomous expression across sexes as reported here are differentially captured by the two sequencing techniques.

L203



L204

L205

L206

L207

L208

L209

L210

L211

L212


L213

L214


L215

L216


**Supplementary Figure 6. Sex differences in the glycolytic rate of proximal tubular (PT) cells.** (a) The extracellular acidification rate (ECAR) was monitored to assess the glycolytic metabolism of male and female PT cells at baseline and after metabolic stress. To induce metabolic stress, the following sequence of drugs was injected: 1μM oligomycin, 0.3μM FCCP, 100mM 2-DG, 1mM Rot/AA. (b) The basal glycolysis ( $p=0.063$ ,  $u=162$ ), maximal glycolytic capacity ( $p=0.0004$ ,  $t=3.832$ ,  $df=42$ ), and glycolytic reserve ( $p<0.0001$ ,  $t=5.331$ ,  $df=42$ ) of male and female PT cells were calculated from the ECAR curves in (a) ( $n=3$  donors/sex;  $n=6-8$  replicates/donor). Group-to-group differences were assessed using two-tailed unpaired t-test for variables following a normal distribution, and Mann-Whitney tests for variables with a non-parametric distribution. \* $p<0.05$ ; \*\*\* $p<0.001$ ; \*\*\*\* $p<0.0001$ . PT, proximal tubule; AUC, area under the curve; ECAR, extracellular acidification rate; FCCP, p-trifluoromethoxy carbonyl cyanide phenyl hydrazine; 2-DG, 2-deoxyglucose; Rot, rotenone; AA: antimycin A.




**Supplementary Figure 7. Additional immune cell phenotyping data.** (a) Expression of immunoglobulin heavy chain genes within the B cell cluster, showing low abundance of class-switched B cells in living donor kidney. No IGHE transcripts were detected. (b) Very few plasma cells marked by high *XBP1* and *CD38* expression were identified. (c) Pathway analysis summary for immune populations, indicating an enrichment in cell-type specific pathways in support of cluster annotations. (d) Differential gene expression between two clusters (MP2 and MP4) of CD16<sup>+</sup> monocyte-like cells identified an enrichment in antigen presentation genes in MP4, and differential expression of *CX3CR1* versus *CXCR4*. (e) Expression of hemoglobin transcripts in the CD45-enriched sequencing datasets, prior to any quality control thresholds or data cleanup steps. Sample HKB28 had the highest abundance of cells positive for hemoglobin transcripts, suggesting more circulating cells in this sample.



**Supplementary Figure 8. Annotation of lymphocyte populations.** Additional feature plots used to annotate of lymphocyte cell types including general T cell markers and subset-specific markers of T resident memory, T effector memory, and T central memory cells, as well as markers of regulatory T cells,  $\gamma\delta$ T cells, innate lymphoid cells and B cells.




**Supplementary Figure 9. Additional supporting data for the identification of resident signatures in kidney lymphocytes.** (a) No FOXP3 expression was noted on T cells, and TCR $\gamma\delta$  staining validated the presence of  $\gamma\delta$ T cells within healthy kidney. (b) Gating strategy for the identification of T helper subsets. (c) Co-expression of CD69 and CD103, characteristic of Trm cells on CD8+ and CD4+ T cells and NK cells of the blood (grey, top row) versus kidney (blue, bottom row). (d) Expression of the chemokine CXCL16 in myeloid cells of the kidney supporting recruitment of CXCR6+ lymphocytes.




**Supplementary Figure 10. Identification of innate lymphoid cell and myeloid populations in healthy human kidney.** (a) The majority of NK cells within kidney are CD56<sup>dim</sup>CD16<sup>+</sup>, while (b) helper ILCs are present in very low abundance in kidney tissue. (c) Predictive identification of CD56<sup>bright</sup>CD16<sup>-</sup> NK cells, ILC3s, and ILC2s within kidney immune transcriptomic data. (d) High expression of *AREG* encoding amphiregulin in kidney NK cells. (f) Gating strategy to remove lymphocytes from the population of interest. (f) Relative to blood, kidney tissue is enriched in CD16<sup>+</sup> myeloid populations, and also allowed for identification of a CD14<sup>+</sup> CD206<sup>+</sup>HLA-DR<sup>+</sup> population likely representing MP1.






**Supplementary Figure 11. Comparison of sequencing data from nephrectomy versus living donor kidney specimens.** (a) Integrated UMAP of kidney immune cells highlighting the contributions of cells derived from living donor versus nephrectomy tissue. (b) Within the T cell compartment, the activation marker *NR4A1* (encoding Nur77) along with checkpoint molecules *PDCD1* (encoding PD-1), *CTLA4* and *TIGIT* were more highly expressed in nephrectomy data. (c), *NR4A1* percent positivity ( $p=0.0152$ ,  $t=3.076$ ,  $df=8$ ) and MFI ( $p=0.4206$ ,  $u=8$ ) on CD3+ T cells, PD-1 percent positivity ( $p=0.6905$ ,  $u=10$ ) and MFI ( $p=0.7024$ ,  $t=0.3961$ ,  $df=8$ ) on CD8+ T cells, CTLA-4 percent positivity ( $p=0.0541$ ,  $t=2.256$ ,  $df=8$ ) and MFI ( $p=0.0851$ ,  $t=1.964$ ,  $df=8$ ) on CD4+ T cells and TIGIT percent positivity ( $p=0.2833$ ,  $t=1.238$ ,  $df=4$ ) on CD3+ T cells were compared between living donor and nephrectomy-derived T cells. (d) Representative plots of CTLA-4 on CD4+ T cells and PD-1 on CD8+ T cells of living donor and nephrectomy-derived cells. (e) NK cells exhibited similar trends at the transcript level with higher *NR4A1*, *AREG*, and *TIGIT* gene expression in nephrectomy data. (f) While Nur77 protein was not differentially detected by percent positivity ( $p=0.5397$ ,  $u=9$ ) or MFI ( $p>0.999$ ,  $u=12$ ), AREG was higher in living donor NK cells by percentage ( $p=0.0006$ ,  $t=5.420$ ,  $df=8$ ) and MFI ( $p=0.0182$ ,  $t=2.959$ ,  $df=8$ ), and TIGIT ( $p=0.0015$ ,  $t=7.728$ ,  $df=4$ ) was more highly detected on nephrectomy NK cells as shown in representative plots in **g**. (h) CD45+ cell elevation in nephrectomy samples did not reach significance ( $p=0.1129$ ,  $t=1.780$ ,  $df=8$ ), however, increased immune cell (CD45+) abundance was observed in 3/5 nephrectomy samples tested,


with high donor heterogeneity in immune cell abundance was observed, indicative of greater differences in tissue microenvironment between nephrectomy specimens. Group-to-group differences were assessed using two-tailed unpaired t-test for variables following a normal distribution, and Mann-Whitney tests for variables with a non-parametric distribution. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . Neph= nephrectomy, MFI=Median Fluorescence Intensity.




**Supplementary Figure 12. Annotation of myeloid populations.** Additional feature plots of myeloid cells supporting cell type annotations, highlighting general myeloid lineage markers, expression of scavenger receptors, and markers of dendritic cells, monocytes and macrophages.



**Supplementary Figure 13. Additional supporting plots for macrophage cell state identification.** (a) Based on our identification of 5 clusters of myeloid lineage cells in living donor kidney, we used SingleCellNet to classify cells from previously published datasets<sup>3,45,46</sup> into our 5 cluster framework. Most cells captured in prior studies were classified as MP5 (CD14<sup>+</sup> monocytes), the smallest cluster in living donors; while MP1 (circled) the largest cluster in living donor data was scarcely represented in previously published data. (b) Merging the three datasets specified in (a) with our living donor dataset confirmed 5 cell states (CS) where living donor data comprised the majority of CS2. A volcano plot depicts genes enriched in CS2 versus the remaining four cell states, supporting that CS2 represents a resident alternatively-activated tissue macrophage population that is uniquely enriched in living donor kidney tissue. (c) Slingshot pseudotime analysis supporting the annotation of CS1 as a transitional myeloid population across two suggested trajectories which placed CS2 and CS0 as the potential trajectory endpoints.




**Supplementary Figure 14. Integration of PBMCs and kidney immune single-cell data.** (a) scRNAseq data from living donor kidney immune cells and PBMCs<sup>48</sup> were integrated using Harmony. (b) Feature plots demonstrating expression of *CD3E*, *NKG7*, *CD79A*, and *CD68* used to annotate major immune populations in the combined dataset. (c) Annotation of major immune populations including T cells, NK cells, B cells and myeloid cells in the integrated PBMC and kidney immune dataset. Feature plots showing gene expression in PBMCs versus living donor kidney data of marker genes used for validation at the protein level including (d)*CXCR4*, (e)*ITGB1*, (f)*CD69*, (g)*CXCR6*, (h)*ITGA4* and (i)*ITGAE*. (j) Differential expression analysis of the T cells and NK cell clusters identifies genes which are upregulated in kidney lymphocytes and may represent kidney-adapted gene expression of these cells.



**Supplementary Figure 15. Optimization of kidney tissue digestion protocol.** (a) Final experimental protocol for generating single-cell RNA sequencing data from living donor kidney. (b) Workflow of options tested in determining the optimal digestion method. (c) Using mouse tissue, a commercial Miltenyi kidney digestion kit was compared to a collagenase and neutral protease mixture to compare yield and viability, with collagenase and neutral protease demonstrating superior yield and comparable viability. (d) Using human nephrectomy tissue, Liberase was compared with collagenase and neutral protease, and flow cytometry was used to determine viability and cell phenotype, where it was determined that collagenase/neutral protease preserved key surface markers that appear to be cleaved by Liberase. (e) Fractions of dissociated human nephrectomy were centrifuged at different speeds to determine cell viability, which was reduced beyond speeds of 400 x g. (f) Using markers of key cell populations, by flow cytometry the contribution of different cell populations to each fraction by differential centrifugation determined that cell types were captured proportionally up to speeds of 400 x g. (g) To optimize yield and preservation of parenchymal cell viability, digestion in either HBSS or RPMI medium with collagenase and neutral protease was tested alongside physical methods of dissociation

l319 including using GentleMACs, a scalpel and a small volume of dissociation medium (n=2), and a scalpel with  
l320 incubation with constant agitation in a shaker (n=2). Over all methods, RPMI preserved parenchymal viability  
l321 better than HBSS, while overall the greatest viability was in using a scalpel and small volume of dissociation  
l322 medium. (h) Viability of immune (CD45<sup>+</sup>) and parenchymal (CD45<sup>-</sup>) populations across physical methods and  
l323 centrifuge speeds to test whether the relative abundance of cell population viability changes with more  
l324 aggressive physical dissociation, where generally more gentle dissociation preserved parenchymal cell viability  
l325 whereas more aggressive physical dissociation improved yield of immune cells. Different GentleMACs™ Tissue  
l326 dissociator settings named based on organ optimized for were tested (liver, intestine, etc). No clear change in  
l327 fractionation was observed in differential centrifugation of the samples. n=1 unless otherwise specified. (i)  
l328 Flow cytometric analysis of kidney parenchymal cells, depicting the capture of live proximal tubular epithelial  
l329 cells (CD10<sup>+</sup>CD13<sup>+</sup>) and endothelial cells (CD31<sup>+</sup>HLA-DR<sup>+/</sup>).  
l330



**Supplementary Figure 16. Ambient RNA contamination.** Feature plots showing the expression of UMOD, a gene specific to cTAL/LOH cells, with widespread low level expression present across all clusters prior to ambient RNA correction and more biologically appropriate expression patterns after ambient RNA correction, demonstrated with a sample dataset (Total9).